levodopa has been researched along with Movement Disorders in 495 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 213 (43.03) | 18.7374 |
| 1990's | 128 (25.86) | 18.2507 |
| 2000's | 89 (17.98) | 29.6817 |
| 2010's | 55 (11.11) | 24.3611 |
| 2020's | 10 (2.02) | 2.80 |
| Authors | Studies |
|---|---|
| Balint, B; Bhatia, KP; Fung, VSC; Morales-Briceno, H | 1 |
| Clarke, CE; Gray, A; Gray, R; Ives, N; Jenkinson, C; McIntosh, E; Muzerengi, S; Patel, S; Rick, C; Wheatley, K; Williams, A; Woolley, R | 1 |
| Artusi, CA; Imbalzano, G; Ledda, C; Lopiano, L; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M | 1 |
| Komatsu, K; Takahashi, M; Ueda, A | 1 |
| Manalo, RVM | 1 |
| Hatano, T; Hattori, N; Iwamuro, H; Izawa, N; Kamagata, K; Kamo, H; Kitahara, E; Kosaki, R; Kubota, M; Ogaki, K; Ogawa, T; Oyama, G; Shimo, Y; Sukigara, T; Umemura, A; Yamashita, Y | 1 |
| Bhidayasiri, R; Panyakaew, P; Thongchuam, Y | 1 |
| Abdelrahman, A; Ahmed, OG; Mahmoud, ME; Monir, DM; Rehan, IF | 1 |
| Deputy, SR; Tilton, AH | 1 |
| Blinova, NM; Derevyanko, HP; Safin, SM | 1 |
| Araki, T; Mukai, T | 1 |
| Antonini, A; Jost, WH | 1 |
| Cova, I; Priori, A | 1 |
| Bonassi, S; Coletti, C; Radicati, FG; Stocchi, F; Vacca, L | 1 |
| Hamel, W; Hariz, M; Köppen, JA; Krack, P; Moll, CKE; Müller, D | 1 |
| Begemann, M; Damen, R; Elbracht, M; Häusler, M; Knopp, C; Kurth, I; Mull, M; Müller, B; Stoppe, A | 1 |
| Pearson, TS; Pons, R | 1 |
| Bhambhani, V; Cullinane, A; Introne, WJ; Lungu, C; Toro, C | 1 |
| Giladi, N; Hausdorff, JM; Hendler, T; Herman, T; Jacob, Y; Rosenberg-Katz, K | 1 |
| Chen, SY; Hsieh, TC; Hung, HY; Lin, SH; Lin, SZ; Tsai, ST | 1 |
| Poewe, W; Seppi, K; Sprenger, FS; Wolf, E | 1 |
| Takeda, A | 1 |
| Alkufri, F; Brown, RG; Burn, DJ; Hindle, JV; Hurt, CS; Landau, S; Samuel, M; Wilson, KC | 1 |
| Bassareo, PP; Cannas, A; Corona, A; Marrosu, F; Mulas, CS; Perra, S; Solla, P | 1 |
| André, E; Calo', G; Cavalcante, JC; Costa, MS; Didonet, JJ; Gavioli, EC; Guerrini, R; Soares-Rachetti, Vde P; Souza, Lde S | 1 |
| Chabardès, S; Debû, B; Espesser, R; Ferraye, M; Fraix, V; Ghio, A; Guirchoum, J; Layani-Zemour, D; Maillet, A; Pinto, S; Pollak, P | 1 |
| Bergeron, Y; Bermejo, MK; Caron, MG; Cyr, M; Gainetdinov, RR; Hossain, MM; Kile, B; Masoud, ST; Miller, GW; Nguyen, LT; Ramsey, AJ; Richardson, JR; Salahpour, A; Siesser, WB; Sotnikova, TD; Vecchio, LM; Wightman, RM | 1 |
| Borden, A; Bourre, B; Brun, L; Derrey, S; Fetter, D; Lefaucheur, R; Maltête, D; Wallon, D | 1 |
| Doyu, M; Ibi, T; Niwa, J; Taguchi, S | 1 |
| Garavaglia, B; Ghezzi, D; Nardocci, N; Tonduti, D; Zibordi, F; Zorzi, G | 1 |
| Chiou, SM | 1 |
| Acs, P; Bokor, M; Bosnyák, E; Deli, G; Dibó, G; Herceg, M; Hidasi, E; Horvath, K; Imre, P; Késmárki, I; Klivényi, P; Komoly, S; Kovács, N; Lajtos, J; Nagy, F; Pál, E; Rigó, E; Takács, K; Takáts, A; Tóth, A; Vécsei, L | 1 |
| Allegri, G; Baumann, CR; Becu-Villalobos, D; Bindoff, LA; Fingerhut, R; Flydal, MI; Hole, M; Konrad, D; Korner, G; Lauber-Biason, A; Martinez, A; Noain, D; Pillai, S; Rassi, A; Scherer, T; Thöny, B; Wueest, S; Ying, M | 1 |
| Czarnecka, A; Konieczny, J; Lenda, T; Lorenc-Koci, E | 1 |
| Alves, G; Bjornestad, A; Forsaa, EB; Larsen, JP; Pedersen, KF; Tysnes, OB | 1 |
| Băjenaru, O; Buraga, I; Constantinescu, A; Ene, A; Mureşan, DF; Perju-Dumbrava, L; Popescu, BO; Popescu, CD; Sabău, M; Simu, M; Szász, JA | 1 |
| Hattori, N | 1 |
| Moro, A; Moscovich, M; Munhoz, RP; Teive, HA | 1 |
| Liepert, J | 1 |
| Bingefors, K; Isacson, D; Kristiansen, IS; Nyholm, D | 1 |
| Deleu, D | 1 |
| Delgado, MR; Donovan, MA; Jou, RL; Kang, PB; Kim, SY; Neilan, EG; Wu, BL | 1 |
| Calabresi, P; Di Filippo, M; Ghiglieri, V; Picconi, B | 1 |
| Nutt, JG | 2 |
| Jenner, P | 1 |
| Olanow, CW; Stocchi, F; Tagliati, M | 1 |
| Kieburtz, K | 1 |
| Brandabur, M; Goetz, CG; Goldman, JG; Sanfilippo, M; Stebbins, GT | 1 |
| Li, XY; Li, YJ; Zhuang, P | 1 |
| Stocchi, F | 1 |
| Comella, C; Elmer, L; Hauser, RA; Lyons, KE; Pahwa, R; Simuni, T; Weintraub, D | 1 |
| García-Horsman, JA; Kääriäinen, TM; Männistö, PT; Piltonen, M | 1 |
| Antonini, A; Bovi, T; Fiaschi, A; Moretto, G; Ottaviani, S; Pasquin, I; Steinmayr, M; Tinazzi, M | 1 |
| Iida, A; Inoue, N; Kakiuchi, T; Kondo, Y; Muramatsu, S; Nakano, I; Nakayama, T; Okuno, T; Ono, F; Suzuki, Y; Takino, N; Terao, K; Tsukada, H | 1 |
| Fernández-Alvarez, E | 1 |
| Beal, MF; Bogdanov, M; Burke, RE; Geghman, K; Jackson-Lewis, V; Li, C; Li, Y; Liu, W; Oo, TF; Przedborski, S; Tang, Y; Wang, L; Zhou, C | 1 |
| Stacy, M | 1 |
| Berardelli, A; Bloise, M; Colosimo, C; Defazio, G; Fabbrini, G; Suppa, A | 1 |
| Cho, JY; Cho, YJ; Hong, KS; Jeon, BS; Kim, HJ; Lee, DH; Park, SY; Seo, SY | 1 |
| Menkes, DL; Silvers, DS | 1 |
| Jog, MS; Kasravi, N | 1 |
| Amanzio, M; Filippi, P; Geminiani, G; Giordano, A; Monteverdi, S; Soliveri, P | 1 |
| McKeith, I | 1 |
| Fisher, R; Jackson, MJ; Jenner, P; Rose, S; Tayarani-Binazir, KA; Zoubiane, G | 1 |
| Beeler, JA; Cao, ZF; Ding, Y; Kang, UJ; Kheirbek, MA; Koranda, J; Murakami, M; Zhuang, X | 1 |
| San Luciano, M; Saunders-Pullman, R | 1 |
| Jackson, MJ; Jenner, P; McCreary, AC; Rose, S; Tayarani-Binazir, K | 1 |
| Brand, M; Labudda, K; Markowitsch, HJ; Mertens, M; Ollech, I; Woermann, FG | 1 |
| Hama, T; Hara, T; Hirayama, M; Ito, M; Nakamura, T; Niimi, Y; Ohno, K; Sobue, G; Uchida, K; Watanabe, H | 1 |
| Armstrong, J; Artuch, R; Barredo-Valderrama, E; Campistol, J; Castro de Castro, P; Cormand, B; Garcia-Cazorla, A; Ormazabal, A; Serrano, M; Toma, C | 1 |
| Bachoud-Lévi, AC; Cleret de Langavant, L; Fénelon, G; Soulas, T; Trinkler, I | 1 |
| Franch, O; Kurtis, MM | 1 |
| Bhidayasiri, R; Ling, H | 1 |
| Ansorge, MS; Esposito, E; Gingrich, JA; Gray, N; Moore, H; Morelli, E; Rebello, TJ; Steele, K | 1 |
| Schnitzler, A; Südmeyer, M; Wojtecki, L | 1 |
| Akdeniz, M; Yaman, A; Yaman, H | 1 |
| Blau, N; Dill, P; Somerville, A; Thöny, B; Wagner, M; Weber, P | 1 |
| Girault, JA | 1 |
| Bernardo, M; Fernández-Egea, E; Martí, MJ; Muñiz, A; Pintor, LP; Rami, L; Sánchez, R; Tolosa, E; Valldeoriola, F | 1 |
| Bianchetti, MG; Falesi, M; Ramelli, GP; Salmina, C; Taddeo, I; Weber, P | 1 |
| Burkhard, PR; Vingerhoets, FJ | 1 |
| Ait Benhaddou, EH; Benjelloun, H; Benomar, A; Lachhab, L; Razine, R; Regragui, W; Yahyaoui, M | 1 |
| Al Hadithy, AF; Alifirova, VM; Brouwers, JR; Fedorenko, OY; Freidin, MB; Govorin, NV; Ivanova, SA; Loonen, AJ; Pechlivanoglou, P; Rudikov, EV; Semke, AV; Sorokina, VA; Wilffert, B; Zhukova, IA | 1 |
| Chan, DC; Chu, QN; Meng, S; Pham, AH | 1 |
| Gotoh, J; Isozumi, K; Iwasawa, S; Mihara, B; Morita, Y; Muramatsu, K; Nihei, Y; Nogawa, S; Ohta, K; Seki, M; Shirai, T; Suzuki, N; Takahashi, K; Tomita, Y; Uematsu, D; Yamaguchi, K; Yasutomi, D | 1 |
| Damier, P; Derkinderen, P; Giumelli, B; Meyniel, C | 1 |
| Brotchie, JM; Fox, SH; Gandy, MN; Huot, P; Johnston, TH; Piggott, MJ; Reyes, MG | 1 |
| Gittis, A | 1 |
| Barrio, S; Caminero, AB; De La Llave, Y; Garcia-Borreguero, D; Granizo, JJ; Larrosa, O; Pareja, JA | 1 |
| Behrens, S; Sommerville, K | 1 |
| van Laar, T | 1 |
| Balash, Y; Bartels, AL; Giladi, N; Gurevich, T; Hausdorff, JM; Schaafsma, JD | 1 |
| HIRSCHMANN, J; MAYER, K | 1 |
| Avila Cobo, MR; Cardozo, A; Katzenschlager, R; Lees, AJ; Tolosa, E | 1 |
| Gadkary, CA; Mummaneni, PV; Quinones-Hinojosa, A; Rosenberg, WS | 1 |
| Cenci, MA; Lundblad, M; Poewe, W; Stefanova, N; Tison, F; Wenning, GK | 1 |
| Linazasoro, G | 1 |
| Battaglia, A; Bracco, F; Chouza, C; Dupont, E; Gershanik, O; Marti Masso, JF; Montastruc, JL | 1 |
| Chapuis, S; Durif, F; Gerbaud, L; Metz, O; Ouchchane, L | 1 |
| Hely, MA; Morris, JG; Reid, WG; Trafficante, R | 1 |
| Carlsson, M; Ganowiak, W; Granérus, AK; Lorefält, B; Pålhagen, S; Toss, G; Unosson, M | 1 |
| Iakhno, NN; Zakharov, VV | 1 |
| Bowron, A; Guttman, M; Hauser, R; Hughes, K; Larsen, JP; LeWitt, P; Oertel, W; Quinn, N; Sethi, K; Stacy, M; Stocchi, F | 1 |
| De Reuck, J; De Weweire, M; Santens, P; Van Maele, G | 1 |
| Comella, C; Widnell, KL | 1 |
| Konitsiotis, S | 1 |
| Baunez, C; Bernardi, G; Calabresi, P; Centonze, D; Gubellini, P; Picconi, B; Pisani, A; Rossi, S | 1 |
| Blau, N; Connolly, MB; Demos, MK; Hyland, K; Lillquist, Y; Makhseed, N; Vallance, HD; Waters, PJ | 1 |
| Mikolenko, I; Skidmore, F; Weiner, W; Weiss, H | 1 |
| Altibrandi, MG; Bentivoglio, A; Caruso, G; Cioni, B; Fiorella, C; Insola, A; Lavano, A; Maina, R; Mazzone, P; Pagni, CA; Signorelli, CD; Sturiale, C; Valzania, F; Zeme, S; Zenga, F | 1 |
| Bronte-Stewart, HM; Hastie, T; Heit, G; Hill, BC; Jefferis, GS; Koop, M; Taylor Tavares, AL | 1 |
| Meixensberger, J; Preul, C; Schwarz, J; Strecker, K; Tittgemeyer, M; Winkler, D | 1 |
| Farrugia, R; Felice, A; Neville, BG; Parascandalo, R | 1 |
| Breitenstein, C; Cohen, LG; Floel, A; Hummel, F; Knecht, S | 1 |
| Al-Bargouthy, G; Costa, S; Iravani, MM; Jackson, MJ; Jenner, P; Kuoppamäki, M; Obeso, JA; Zeng, BY | 1 |
| Lang, AE; Miyasaki, J; Olanow, CW; Stoessl, AJ; Suchowersky, O | 1 |
| Goldstein, DS | 1 |
| Bergamaschi, A; Bernardi, G; Brusa, L; Fedele, E; Galante, A; Galati, S; Lunardi, G; Magrini, A; Pierantozzi, M; Pietroiusti, A; Sancesario, G; Stanzione, P; Stefani, A | 1 |
| Fujiki, N; Sasaki, H; Soma, H; Takei, A; Yabe, I; Yanagihara, T | 1 |
| Defazio, G; Lamberti, P; Livrea, P; Martino, D; Zoccolella, S | 1 |
| Grant, PE; Sims, KB; Venna, N | 1 |
| Alm, H; Andrén, PE; Bezard, E; Crossman, AR; Kultima, K; Lönnstedt, I; Scholz, B; Sköld, K; Svensson, M | 1 |
| de Noordhout, AM; Santens, P | 1 |
| Cenci, MA; Lindgren, HS; Lundblad, M; Ohlin, KE; Rylander, D | 1 |
| Blau, N; Friedman, J; Hyland, K; MacCollin, M | 1 |
| Cenci, MA | 1 |
| Angersbach, D; Buchwald, B; Jost, WH | 1 |
| Kim, JS; Lee, KS; Song, IU | 1 |
| Archer, T; Fredriksson, A | 1 |
| Borges, V; Ferraz, HB; Silva, SM; Souza, RG | 1 |
| Ha Paek, S; Jeon, BS; Kim, HJ; Kim, JY | 1 |
| Brown, P; Eusebio, A | 1 |
| Djaldetti, R; Melamed, E; Ziv, I | 1 |
| Bareggi, SR; Bet, L; Bondiolotti, G; Meola, G; Pacei, F; Schapira, AH | 1 |
| de Haan, RJ; Post, B; Speelman, JD | 1 |
| Crucian, GP; Drago, V; Foster, PS; Heilman, KM; Skidmore, F; Skoblar, BM | 1 |
| Hovestadt, A; Lees, AJ; van Laar, T; Volkmann, J; Wolters, E | 1 |
| Azulay, JP; Bourdeix, I; Durif, F; Rerat, K; Rogez, R; Tranchant, C | 1 |
| Hunter, KR | 1 |
| Marsden, CD | 4 |
| Still, CN | 1 |
| Yung, CY | 1 |
| Lakke, JP; van der Burg, W; Wiegman, J | 1 |
| Bartholini, G | 1 |
| Hershey, L; Reilly, DK; Rivera-Calimlim, L; Shoulson, I | 1 |
| Birkmayer, W; Knoll, J; Riederer, P; Youdim, MB | 1 |
| Albizzati, MG; Bassi, S; Frattola, L; Spano, PF; Trabucchi, M | 1 |
| Koga, I; Nishikawa, T; Tanaka, M; Tsuda, A; Uchida, Y | 1 |
| Selby, G | 1 |
| Narabayashi, H | 6 |
| Birkmayer, W; Danielczyk, W; Riederer, P | 1 |
| Parkes, JD | 1 |
| Ballard, P; Langston, JW | 1 |
| Allain, H; Bentue-Ferrer, D; Pape, D; Reymann, JM; Sabouraud, O; van den Driessche, J | 1 |
| Agnoli, A; Baldassarre, M; Bocola, V; Del Roscio, S; Denaro, A; Ruggieri, S | 1 |
| Bragdon, AC; Coffey, CE; Ferren, EL; Hurwitz, BJ; Olanow, CW; Ross, DR | 1 |
| Hirayama, K; Yamada, T | 1 |
| Kameyama, M; Nakamura, S | 1 |
| Bassi, S; Frattola, L; Trabucchi, M | 1 |
| Casey, DE | 2 |
| Alexander, MP; Direnfeld, LK; Feldman, RG; Kelly-Hayes, M | 1 |
| González, ER | 1 |
| Casas Parera, I; Diaz, S; Fernández Pardal, MM; Gatto, E; Micheli, F | 1 |
| Boonen, S; Celen, H; Dom, R; Pelemans, W | 1 |
| Iacono, RP; Lonser, RR; Oh, A; Yamada, S | 1 |
| Brooks, DJ; Weeks, RA | 1 |
| Bentlage, C; Björklund, A; Nikkhah, G; Olsson, M | 1 |
| Bertini, E; Di Capua, M | 1 |
| Caparros-Lefebvre, D; Duhamel, A; Pécheux, N; Petit, H; Petit, V | 1 |
| Dobato, JL; Giménez-Roldán, S; Mateo, D | 1 |
| Nezlin, L; Sakharov, D; Voronezhskaya, E | 1 |
| Ben Shlomo, Y; Daniel, SE; Magalhães, M; Quinn, NP; Wenning, GK | 1 |
| Calne, DB; Chu, NS; Huang, CC; Lu, CS | 1 |
| Playford, ED | 1 |
| Brin, IL; Drozdov, AZ; Filatova, TS; Kogan, BM; Kovaleva, IA | 1 |
| Larmande, P; Maillot, F; Palisson, E; Saikali, I | 1 |
| Albani, C; Bächli, E | 1 |
| Broe, GA; Hely, MA; Margrie, S; Morris, JG; O'Sullivan, DJ; Rail, D; Reid, WG; Williamson, PM | 1 |
| Kurisaki, H; Masuda, N; Nishiyama, K | 1 |
| Imai, H | 1 |
| Quinn, NP | 1 |
| Gancher, ST; Nutt, JG | 1 |
| Akiguchi, I; Nakamura, S | 1 |
| Guillard, A | 3 |
| Chen, RC; Chiu, HC; Wang, M; Wu, RM | 1 |
| Hirose, K; Isozaki, E; Miyamoto, K; Noda, K; Oda, M; Tanabe, H | 1 |
| Atchison, PR; Frackowiak, RS; Marsden, CD; Thompson, PD | 1 |
| Achiron, A; Goldberg, H; Goren, M; Melamed, E; Sroka, H; Ziv, I; Zoldan, Y | 1 |
| Lang, AE; Riley, DE | 1 |
| Calne, DB; Chu, NS; Hochberg, F; Huang, CC; Lilienfeld, D; Lu, CS; Olanow, W | 1 |
| Bennett, JP; Schuh, LA | 1 |
| Auff, E; Doppelbauer, A; Fertl, E; Waldhauser, F | 1 |
| Albani, C; Buck, A | 1 |
| Chollet, F; Marc-Vergnes, JP; Montastruc, JL; Rascol, A; Rascol, OJ; Sabatini, U | 1 |
| Yokochi, M | 1 |
| Imai, H; Kondo, T; Nakamura, T; Narabayashi, H | 1 |
| Horstink, MW; Jansen, EN; Roos, RA; Wolters, EC | 1 |
| Baronti, F; Bramante, L; Monge, A; Ruggieri, S; Stefano, E; Stocchi, F; Viselli, F | 1 |
| Bösch, S; Kreczy-Kleedorfer, B; Künig, G; Neubauer, M; Ransmayr, G; Wagner, M | 1 |
| Fornadi, F; Pantelatos, A | 1 |
| Blankson, S; Daniel, SE; Hughes, AJ; Lees, AJ | 1 |
| Date, ES; Schwartz, M; Seibel, MO; Zeiner, H | 1 |
| De Deyn, PP; Gonce, M; Jacquy, J; Van den Kerchove, M | 1 |
| Caraceni, T; Fetoni, V; Geminiani, GC; Genitrini, S; Giovannini, P; Girotti, F; Parati, EA; Soliveri, P; Testa, D | 1 |
| Campistol, J; Garaizar, C; Prats, JM | 1 |
| Benson, R; Charlton, CG; Crowell, BG; Shockley, D | 1 |
| Brefel, C; Fuell, D; Lees, AJ; Montastruc, JL; Pirtosek, Z; Rascol, O; Senard, JM | 1 |
| Barbanti, P; Bramante, L; DePandis, F; Fabbrini, G; Manfredi, M; Ruggieri, S; Stocchi, F; Vacca, L | 1 |
| Bédard, PJ; Blanchet, PJ; Di Paolo, T; Gomez-Mancilla, B | 1 |
| Agid, Y; Bonnet, AM; Carpentier, AF; Vidailhet, M | 1 |
| Burns, RS; Davis, TL; Roznoski, M | 1 |
| Coltz, JD; Ebner, TJ; Gupta, A; Johnson, MT; Kipnis, AN; Silverstein, P; Zwiebel, F | 1 |
| Adler, CH; Ahlskog, JE; Muenter, MD; Wright, KF | 1 |
| Bonuccelli, U; Colzi, A; Del Dotto, P; Dubini, A; Grimaldi, R; Lucetti, C; Pardini, C | 1 |
| Adena, MA; Broe, GA; Hely, MA; Morris, JG; O'Sullivan, DJ; Reid, WG; Williamson, PM | 1 |
| Collard, M; Hirsch, E; Marescaux, C; Picard, F; Salmon, E | 1 |
| Dubinsky, R; Hubble, JP; Koller, WC; Lyons, K; McGuire, D; Pahwa, R | 1 |
| Bonamartini, A; Ruggieri, S; Stocchi, F; Vacca, L | 1 |
| Koller, WC | 1 |
| Allard, P; Bédard, PJ; Blanchet, PJ; Grégoire, L; Tardif, F | 1 |
| Blanchet, PJ; Chase, TN; Metman, LV; Mouradian, MM | 1 |
| Fujita, T; Hoshino, S; Nakamagoe, K; Ohkoshi, N; Shoji, S | 1 |
| Carvey, PM; Goetz, CG; Ling, ZD; Niederman, F; Pappert, EJ; Stebbins, GT | 1 |
| Hoyt, L; McSherry, G; Mendelson, J; Mintz, M; Oleske, J; Tardieu, M | 1 |
| Marsden, CD; Steiger, MJ; Thompson, PD | 1 |
| Lee, ST; Lu, CS | 1 |
| Burguera, JA; Chacón, J; Forcadell, F; Giménez-Roldán, S; Liaño, H; Tolosa, E | 1 |
| Fahn, S; Klatka, LA; Liu, Y; Louis, ED | 1 |
| Hariz, M; Johansson, F; Malm, J; Nordh, E | 1 |
| Campbell, G; Chaudhuri, KR; D'Olhaberriague, L; Jellinger, K; Litvan, I; Mangone, CA; McKee, A; Pearce, RK; Verny, M | 1 |
| Marsden, CD; Nordera, G; Stocchi, F | 1 |
| Hurtig, HI | 1 |
| Pulst, SM; Sutton, JP | 1 |
| Garcia, S; Gershanik, O; Gomez Arevalo, G; Jorge, R; Scipioni, O | 1 |
| Carter, JH; Lea, ES; Nutt, JG; Woodward, WR | 1 |
| Blaney, TJ; Chandonait, SE; Emerich, DF; Lindner, MD; Mullins, TD; Plone, MA; Sherman, SS; Stott, JA; Winn, SR | 1 |
| Boonkongchuen, P; Churchyard, A; Lees, AJ; Mathias, CJ | 1 |
| Blanchet, P; Chase, TN; Klaassen, AA; Metman, LV; Mouradian, MM; van den Munckhof, P | 1 |
| Brooks, DJ; Lees, AJ; Turjanski, N | 1 |
| Bioulac, B; Boraud, T; Gross, C; Guehl, D; Julien, J; Rougier, A | 1 |
| de Yébenes, JG; García-Ruiz, PJ; Sánchez-Pernaute, R | 1 |
| Gordin, A; Jenner, P; Marsden, CD; Smith, LA | 1 |
| Benabid, AL; Krack, P; Limousin, P; Pollak, P | 1 |
| Chase, TN | 1 |
| Bracco, F; Chouza, C; Dupont, E; Gershanik, O; Marsden, CD; Marti Masso, JF; Montastruc, JL; Rinne, UK | 1 |
| Benabid, AL; Benazzouz, A; Hoffmann, D; Koudsie, A; Krack, P; Le Bas, JF; Limousin, P; Pollak, P | 1 |
| Nozawa, T | 1 |
| Ellis, KL; Speed, J | 1 |
| Blasko, J; Burkhart, WA; Goiney, RC; Grimm, P; Posewitz, A; Shumway-Cook, A; Vermeulen, SS; Young, RF | 1 |
| Baas, H; Harder, S | 1 |
| Bassi, A; Bernardi, G; Formisano, R; Peppe, A; Piccolino, M; Pierantozzi, M; Santilli, AM; Semprini, R; Stanzione, P | 1 |
| Baxendale, RH; Bennett, NK; Branton, R; Campbell, JM; Clarke, DJ; Davies, RW; Favor, G; Payne, AP; Russell, D; Simpson, E; Sutcliffe, RG; Tsang, C | 1 |
| Hempel, AG; Maaty, MA; Sage, JI; Wagner, ML | 1 |
| Blanchet, PJ; Chase, TN; Del Dotto, P; van den Munckhof, P; Verhagen Metman, L | 1 |
| Katayama, S; Khoriyama, T; Mao, JJ; Nakamura, S; Oka, M; Tahara, E; Watanabe, C; Yamamura, Y | 1 |
| Bardin, PG; Battistin, L; Ferro-Milone, F; Ravenna, C; Reboldi, G; Toso, V | 1 |
| Bédard, PJ; Doan, VD; Grégoire, L; Grondin, R | 1 |
| Rinne, UK | 2 |
| Oertel, WH; Pinter, MM; Pogarell, O | 1 |
| Brown, P; Lees, AJ; Wang, HC | 1 |
| Antonio Molina, J; Figueiras-Méndez, R; Jiménez-Jiménez, FJ; López-Pino, MA; Magariños, C; Marín-Zarza, F; Martínez, V; Ortí-Pareja, M | 1 |
| Colosimo, C; De Michele, M | 1 |
| Asano, M; Kohanawa, M; Min, Y; Minagawa, T | 1 |
| Djaldetti, R; Galili-Mosberg, R; Melamed, E; Ziv, I; Zoldan, J | 1 |
| Durif, F | 1 |
| Behari, M; Denny, AP | 1 |
| de Mello, MT; Poyares, DL; Tufik, S | 1 |
| Calne, DB; de la Fuente-Fernández, R; Kishore, A; Mak, EK; Pal, PK; Ruth, TJ; Schulzer, M; Snow, BJ; Stoessl, AJ; Vingerhoets, FJ | 1 |
| Cosentino, C; Micheli, F; Scorticati, MC; Torres, L | 1 |
| Ferreira, JJ; Rascol, O | 1 |
| Campbell, JM; Davies, RW; Favor, G; Gilmore, DP; Growney, CA; Kennedy, AK; Payne, AP; Russell, D; Stone, TW | 1 |
| Karlsen, K; Larsen, JP; Tandberg, E | 1 |
| Hagell, P | 1 |
| Vingerhoets, F | 1 |
| Bares, M; Hejduková, B; Hortová, H; Jech, R; Kanovský, P; Mecír, P; Rektor, I; Rektorová, I; Roth, J; Růzicka, E; Streitová, H | 1 |
| Obeso, JA; Olanow, CW | 1 |
| Heikkilä, M; Jenner, P; Lindén, IB; Pearce, RK | 1 |
| Avison, MJ; Berger, JR; Maragos, WF; Nath, A; Schmitt, FA | 1 |
| Ahangar, B; Burke, DT; Chae, H; Frates, EP | 1 |
| Ohye, C | 1 |
| Blatt, JL; Blond, S; Bourriez, JL; Defebvre, LJ; Destée, A; Duhamel, A; Guieu, JD; Krystkowiak, P; Périna, M | 1 |
| Aktan, S; Bekiroglu, N; Gunal, DI; Nurichalichi, K; Tuncer, N | 1 |
| Barbeau, A | 3 |
| Cohen, HP; Maritn, WE; Tolosa, ES | 1 |
| Winkelmann, W | 1 |
| Marsden, CD; Parkes, JD | 1 |
| Birket-Smith, E; Dupont, E; Hansen, E; Hyyppä, M; Marttila, R; Mikkelsen, B; Pakkenberg, H; Presthus, J; Rinne, UK | 1 |
| Elsworth, JD; Kohout, LJ; Lees, AJ; Sandler, M; Shaw, KM; Stern, GM; Youdim, MB | 1 |
| Lees, AJ; Shaw, KM; Stern, GM | 1 |
| Lander, CM; Lees, A; Stern, G | 1 |
| Cotzias, GC; Mena, I; Mendez, JS; Papavasiliou, PS | 1 |
| Moskowitz, MA; Wurtman, RJ | 1 |
| Klawans, H | 1 |
| Klawans, HL; Weiner, WJ | 1 |
| Tolosa, ES | 1 |
| Sears, ES | 1 |
| Calne, DB; Eisler, T | 1 |
| Battista, AF; Goldstein, M; Miyamoto, T | 1 |
| Hartmann, E | 1 |
| Zenkov, LR | 1 |
| Cler, JM; Mathé, JF; Venisse, JL | 1 |
| Marais, C | 1 |
| Durand, JP; Gautier, JC | 1 |
| Godwin-Austen, RB | 1 |
| Antal, J; Antóny, M; Csanaky, A; Csanda, E | 1 |
| Lai, C; Tolosa, ES | 1 |
| Gerlach, J | 1 |
| Anlezark, GM; Marsden, CD; Meldrum, BS | 1 |
| Adamkov, J; Drobný, M; Fundárek, J; Svaleková, A | 1 |
| Dasheiff, RM | 1 |
| Bathien, N; Rondot, P | 1 |
| McDowell, FH; Miller, ST; Papavasiliou, PS; Rosal, V | 1 |
| Berrios, N; Marshall, JF | 1 |
| Asano, T; Matsumoto, Y; Mimura, Y; Mino, S; Nishimoto, A; Ohmoto, T; Yoshimura, Y | 1 |
| Sharpless, NS; Tabaddor, K; Wolfson, LI | 1 |
| Barrett, RE; Cote, LJ; Fahn, S; Isgreen, WP; Snider, SR | 1 |
| Davidson, DL; Mawdsley, C; Pullar, IA; Wilson, H; Yates, CM | 1 |
| Goetz, CG; Klawans, HL; Nausieda, PA; Weiner, WJ | 1 |
| Bédard, P; Marsden, CD; Parkes, JD | 1 |
| Direnfeld, L; Marotta, J; Seeman, P; Spero, L | 1 |
| Rinne, UK; Siirtola, T; Sonninen, V | 1 |
| Kaneko, Y; Kowada, M; Kumashiro, H; Yashima, Y | 1 |
| Fisher, MA; Milner-Brown, HS; Weiner, WJ | 1 |
| Barry, VC; Klawans, HL | 1 |
| Arfel, G; Derome, P; Guiot, G; Jedynak, P; Walter, S | 1 |
| Barbeau, A; Gonce, M | 1 |
| Boucher, R; Dankova, J; Larochelle, L; Péchadre, JC; Poirier, LJ | 1 |
| Filion, M; Larochelle, L; Péchadre, JC; Poirier, LJ | 1 |
| Jasper, HH | 1 |
| Chase, TN; Glaubiger, GA; Shoulson, I | 1 |
| Osvaldo, NR | 1 |
| Anagnoste, B; Battista, AF; Goldstein, M; Ogawa, M | 1 |
| Barbeau, A; Cloutier, T; Inoué, N | 1 |
| Denny-Brown, D; Yanagisawa, N | 1 |
| Hayek, J | 1 |
| Fleming, AM; Lenman, JA; Reid, A; Turnbull, MJ | 1 |
| Duvoisin, RC | 2 |
| Aunis, D; Collard, M; Coquillat, G; Mandel, P; Miras Portugal, MT; Rohmer, F; Warter, JM | 1 |
| Barbeau, A; Roy, M | 1 |
| Cote, LJ; Fahn, S; Isgreen, WP; Snider, SR | 1 |
| Feigenson, JS; McDowell, FH; Sweet, RD | 1 |
| Piccirilli, M; Quartesan, R | 1 |
| Ohtomo, E | 1 |
| Bergen, D; Goetz, C; Klawans, HL | 1 |
| Gabreëls, FJ; Joosten, EM; Keyser, A; Korten, JJ | 1 |
| Marsden, CD; Parkes, JD; Tarsy, D | 1 |
| Sassin, JF | 1 |
| Goodgold, A; Jonas, S; Leibowitz, M; Lieberman, A | 1 |
| Bell-Midura, M; Cotzias, GC; Mendez, JS; Papavasiliou, PS; Tolosa, ES | 1 |
| Boucher, R; Dankova, J; Poirier, LJ | 1 |
| Constantinidis, J; Dick, P; Tissot, R; Yanniotis, G | 1 |
| Boismare, F; Boquet, J | 1 |
| Klawans, HL; Margolin, DI | 1 |
| Dolphin, A; Jenner, P; Marsden, CD | 1 |
| Birket-Smith, E | 1 |
| Kishikawa, H; Ohmoto, T | 1 |
| Cotzias, GC; Hsieh, RS; Kraner, HW; Miller, ST; Papavasiliou, PS | 1 |
| Bergen, D; Klawans, HL; Topel, JL | 1 |
| Crossett, P; Dana, N; Klawans, HL | 1 |
| Costall, B; Naylor, RJ | 1 |
| Crosset, P; Dana, N; Klawans, HL; Margolin, DI | 1 |
| Birkmayer, W; Linauer, W; Riederer, P; Youdim, MB | 1 |
| Mawdsley, C | 1 |
| Agnoli, A; Carolei, A; Cerbo, R; Meco, G; Ruggieri, S; Zamponi, A | 1 |
| Stimmel, GL | 1 |
| Deffond, D; Durif, F; Eschalier, A; Tournilhac, M | 1 |
| Astarloa, R; de la Vega, L; de Yébenes, JG; Mena, MA; Sánchez, V | 1 |
| Lees, AJ; Merello, M | 1 |
| Marsden, CD; Pires, M; Quinn, NP; Scaravilli, F; Steiger, MJ | 1 |
| Beaman, BL; Ogata, SA | 1 |
| Beaman, BL; Kohbata, S | 1 |
| Fahn, S; Flaster, E; Giladi, N; Guillory, S; Kostic, V; McMahon, D; Przedborski, S | 1 |
| Mark, MH; Sage, JI | 1 |
| Coni, RJ; Cowger, M; Factor, SA; Rosenblum, EL | 1 |
| Araki, K; Arima, M; Sakuragawa, N; Yoshikawa, H | 1 |
| Bressman, SB; Greene, PE | 1 |
| Bruggi, P; Martignoni, E; Nappi, G; Pacchetti, C; Sibilla, L; Turla, M | 1 |
| Imai, H; Narabayashi, H | 1 |
| Avoni, P; Baruzzi, A; Contin, M; Cortelli, P; Martinelli, P; Procaccianti, G; Riva, R | 1 |
| Ahlskog, JE; Bailey, PA; Bell, GN; Blexrud, MD; Carmichael, SW; Kelly, PJ; Stoddard, SL; Tyce, GM; van Heerden, JA; Windebank, AJ | 1 |
| Luquin, MR; Obeso, JA; Vaamonde, J | 1 |
| Butler, IJ; Caskey, TC; Jankovic, J; Stout, JT | 1 |
| Deleu, D; Ebinger, G; Jacques, M; Michotte, Y | 1 |
| Gilley, DW; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Dickins, QS; Dobson, J; Rodnitzky, RL | 1 |
| Bush, DF; Hutton, JT; Liss, CL; Morris, JL; Reines, S; Smith, ME | 1 |
| Le, W | 1 |
| Reynolds, CM; Riklan, M; Stellar, S | 1 |
| Smith, RG; Wilson, JA | 1 |
| d'Anglejan Chatillon, J | 1 |
| Agid, Y; Bonnet, AM; Dubois, B; Kefalos, J; Pourcher, E | 1 |
| Boyce, S; Clarke, CE; Crossman, AR; Robertson, RG; Sambrook, MA | 2 |
| Bovingdon, M; Frankel, JP; Kempster, PA; Lees, AJ; Stern, GM; Webster, R | 1 |
| Gubskiĭ, LV | 1 |
| Jenner, P; Marsden, CD; Rupniak, NM | 1 |
| Cooper, DR; Jenner, P; Marrel, C; Marsden, CD; Testa, B; van de Waterbeemd, H | 1 |
| Simpson, GM; Stephanos, MJ; Yadalam, KG | 1 |
| Ohmoto, T | 1 |
| Fernandez Pardal, M; Gatto, M; Micheli, F; Perez y Gonzalez, N | 1 |
| Eadie, MJ | 1 |
| Bédard, MA; Godbout, R; Montplaisir, J; Poirier, G | 1 |
| Brodeur, C; Godbout, R; Marinier, R; Montplaisir, J | 1 |
| Caradoc-Davies, TH | 1 |
| Agnoli, A; Baronti, F; Denaro, A; Ruggieri, S; Stocchi, F | 1 |
| Csanda, E; Takáts, A; Tárczy, M | 1 |
| Dubuis, R | 1 |
| Fornadi, F; Ulm, G | 1 |
| Martin, WR | 1 |
| Bioulac, B; Doudet, D; Gross, C; Lebrun-Grandié, P | 1 |
| Aymard, N; Holzer, J; Rondot, P; Ziegler, M | 1 |
| Marion, MH; Marsden, CD; Quinn, NP | 1 |
| Ludin, HP | 1 |
| D'Andrea, G; Durisotti, C; Ferro-Milone, F; Lion, P; Lorizio, A; Nordera, GP | 1 |
| Baas, H; Fischer, PA | 1 |
| Lees, AJ; Poewe, WH; Stern, GM | 1 |
| Heersema, T; Jansen, EN; Meerwaldt, JD; Speelman, JD; van Manen, J | 1 |
| Fahn, S | 1 |
| Jansen, EN; Meerwaldt, JD | 1 |
| LeWitt, PA | 1 |
| Lees, AJ | 1 |
| Aljanati, R; Caamano, JL; Chouza, C; de Medina, O; Gonzales Panizza, V; Romero, S; Scarmelli, A | 1 |
| Dupont, E; Hansen, E; Jensen, NO; Mikkelsen, B; Mikkelsen, BO | 1 |
| Siegfried, J | 1 |
| Chase, TN; Fabbrini, G; Juncos, JL; Mouradian, MM | 1 |
| Araki, S; Kumamoto, T; Nakagawa, T; Uchino, M; Uyama, E | 1 |
| Bourke, CA | 1 |
| Battistin, L; Bracco, F; Saladini, M | 1 |
| Agnoli, A; Brughitta, G; Ruggieri, S; Stocchi, F | 1 |
| Bédard, PJ; Boucher, R; Di Paolo, T; Falardeau, P | 1 |
| Caraceni, TA; Giovannini, P; Girotti, F; Parati, E | 1 |
| Benecke, R; Day, BL; Dick, JP; Marsden, CD; Rothwell, JC | 1 |
| Hoerning, E; Kaplan, PE; Sohn, DG | 1 |
| Colpaert, FC | 1 |
| Bouchard, S | 1 |
| Montastruc, JL; Rascol, A; Rascol, O; Senard, JM | 1 |
| Indo, T; Takahashi, A | 1 |
| Critchley, P; Parkes, D | 1 |
| Jankovic, J | 1 |
| Duvoisin, RC; Sage, JI | 1 |
| Bakker, K; Bruno, G; Chase, TN; Ruggieri, S; Tamminga, CA | 1 |
| Close, SP; Marriott, AS; Pay, S | 1 |
| Calne, DB; Jaffe, M; Larsen, TA; LeWitt, PA; Newman, RP | 1 |
| Espadaler Medina, JM | 1 |
| Morris, JG | 1 |
| Hershey, LA | 1 |
| Benvenuti, F; Bindi, A; Costantini, S; De Scisciolo, G; Pantaleo, T; Rossi, L; Zappoli, R | 1 |
| Kondo, T; Nakajima, Y; Narabayashi, H | 1 |
| Gillingham, FG; Tsukamoto, Y | 1 |
| Carlsson, A | 1 |
| Bédard, P; Boucher, R; Langelier, P; Larochelle, L; Parent, A; Poirier, LJ; Roberge, AG | 1 |
| Poirier, LJ | 1 |
| Parkes, D | 1 |
| Glasgow, GL; Henley, JW; Willoughby, EW | 1 |
| Fischer, GJ; Quandt, J; Sommer, H | 1 |
| Ferrari, E | 1 |
| Rosin, AJ | 1 |
| Cotzias, GC; Mena, I; Mendez, J; Papavasiliou, PS | 1 |
| Ericsson, AD; McCann, DS | 1 |
| McDowell, FH; Sweet, RD | 2 |
| Allen, JG; Caine, DB; Claveria, LE | 1 |
| Cotzias, GC; Mena, I; Papavasiliou, PS | 1 |
| Markham, CH | 1 |
| Yahr, MD | 1 |
| Cotzias, GC | 1 |
| Mayer, RF | 1 |
| Chakravorty, NK | 1 |
| Klawans, HL; Topel, JL | 1 |
| Diamond, SG; Markham, CH; Treciokas, LJ | 1 |
| Borromei, A; Manzini, A | 1 |
| Strouthidis, TM | 1 |
| Cane, DB | 1 |
85 review(s) available for levodopa and Movement Disorders
| Article | Year |
|---|---|
Parkinsonism and dystonia: Clinical spectrum and diagnostic clues.
Topics: Animals; Dystonia; Dystonic Disorders; Humans; Levodopa; Movement Disorders; Parkinsonian Disorders | 2022 |
SARS-CoV-2 vaccination, Parkinson's disease, and other movement disorders: case series and short literature review.
Topics: Carbidopa; COVID-19; COVID-19 Vaccines; Deep Brain Stimulation; Drug Combinations; Humans; Immunization, Secondary; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Treatment Outcome; Vaccination | 2022 |
Treatment of Disorders of Tone and Other Considerations in Pediatric Movement Disorders.
Topics: Autoimmune Diseases; Cerebral Palsy; Child; Dyskinesias; Humans; Levodopa; Metabolism, Inborn Errors; Movement Disorders; Muscle Tonus; Neurodegenerative Diseases; Physical Therapy Modalities; Treatment Outcome | 2020 |
[Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Duodenum; Humans; Infusions, Intravenous; Infusions, Parenteral; Jejunum; Levodopa; Movement Disorders; Parkinson Disease | 2018 |
Diagnostic biomarkers for Parkinson's disease at a glance: where are we?
Topics: alpha-Synuclein; Biomarkers; Brain; Cognition Disorders; Constipation; Depression; Early Diagnosis; Genetic Predisposition to Disease; Humans; Inflammation; Levodopa; Metabolomics; Microbiota; Movement Disorders; Neuroimaging; Olfaction Disorders; Parkinson Disease; REM Sleep Behavior Disorder; Symptom Assessment; Vision Disorders | 2018 |
The Pioneering and Unknown Stereotactic Approach of Roeder and Orthner from Göttingen. Part II: Long-Term Outcome and Postmortem Analysis of Bilateral Pallidotomy in the Pre-Levodopa Era.
Topics: Adult; Aged; Chorea; Diagnosis; Dyskinesias; Female; Globus Pallidus; Humans; Imaging, Three-Dimensional; Levodopa; Male; Middle Aged; Movement Disorders; Pallidotomy; Parkinson Disease; Psychosurgery; Stereotaxic Techniques; Thalamus; Treatment Outcome; Tremor | 2018 |
Movement Disorders in Children.
Topics: Child; Child, Preschool; Diet, Ketogenic; Dopamine Agents; Female; Humans; Infant; Levodopa; Movement Disorders | 2019 |
Movement disorders: advances in 2015.
Topics: Animals; Antiparkinson Agents; Carbidopa; DNA-Binding Proteins; Drug Combinations; Humans; Levodopa; Mitochondrial Proteins; Movement Disorders; Parkinson Disease; Transcription Factors | 2016 |
Molecular mechanisms underlying levodopa-induced dyskinesia.
Topics: Antiparkinson Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Humans; Levodopa; Movement Disorders; Neuronal Plasticity; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2008 |
Pharmacokinetics and pharmacodynamics of levodopa.
Topics: Antiparkinson Agents; Humans; Kinetics; Levodopa; Motor Activity; Movement Disorders; Parkinson Disease; Time Factors | 2008 |
Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
Topics: Antiparkinson Agents; Denervation; Dopamine; Drug Administration Schedule; Humans; Levodopa; Movement Disorders; Parkinson Disease; Time Factors | 2008 |
Treatment of levodopa-induced motor complications.
Topics: Adsorption; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dopamine Agonists; Drug Administration Schedule; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Motor Activity; Movement Disorders; Parkinson Disease; Safety | 2008 |
Therapeutic strategies to prevent motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Humans; Levodopa; Movement Disorders; Parkinson Disease | 2008 |
The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Topics: Animals; Dopamine Agents; Humans; Levodopa; Movement Disorders; Parkinson Disease; Time Factors | 2009 |
Treatment of early Parkinson's disease. Part 1.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Patient Compliance | 2009 |
Movement disorders in children: recent advances in management.
Topics: Age Distribution; Age of Onset; Baclofen; Benzodiazepines; Child; Child, Preschool; Cholinergic Antagonists; Dopamine Agents; Drug Therapy, Combination; Dyskinesias; Early Diagnosis; Electromyography; Female; Humans; Incidence; Infant; Levodopa; Male; Movement Disorders; Physical Examination; Prognosis; Risk Assessment; Severity of Illness Index; Sex Distribution; Spain; Treatment Outcome | 2009 |
Substance abuse and movement disorders.
Topics: Alcoholism; Animals; Apomorphine; Humans; Levodopa; Movement Disorders; Parkinson Disease; Substance Withdrawal Syndrome; Substance-Related Disorders | 2009 |
[Current treatment strategies for Parkinson's disease].
Topics: Aged; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Apomorphine; Critical Care; Deep Brain Stimulation; Dementia; Depression; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Europe; Female; Humans; Infusion Pumps, Implantable; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Psychotic Disorders; Sleep Wake Disorders; Tremor | 2011 |
How best to address these common movement disorders.
Topics: Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Anticonvulsants; Antiparkinson Agents; Essential Tremor; Humans; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Practice Guidelines as Topic; Primidone; Propranolol; Tetrabenazine; Tourette Syndrome; Treatment Outcome | 2011 |
Signaling in striatal neurons: the phosphoproteins of reward, addiction, and dyskinesia.
Topics: Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Cyclic AMP-Dependent Protein Kinases; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Humans; Levodopa; MAP Kinase Signaling System; Models, Neurological; Movement Disorders; Nerve Tissue Proteins; Neuronal Plasticity; Neurons; Phosphoproteins; Phosphorylation; Protein Processing, Post-Translational; Receptors, Glutamate; Reward; Substance-Related Disorders | 2012 |
[Resistance to treatment in movement disorders].
Topics: Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Drug Resistance; Essential Tremor; Humans; Levodopa; Movement Disorders; Neurosurgery; Parkinson Disease; Treatment Failure | 2012 |
Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.
Topics: Age Factors; Antiparkinson Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Humans; Levodopa; Motor Activity; Movement Disorders; Parkinson Disease; Time Factors; Treatment Outcome | 2003 |
Entacapone/levodopa/carbidopa combination tablet: Stalevo.
Topics: Administration, Oral; Antiparkinson Agents; Carbidopa; Catechols; Clinical Trials as Topic; Drug Combinations; Humans; Levodopa; Movement Disorders; Nitriles; Parkinson Disease; Tablets | 2003 |
Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Globus Pallidus; Humans; Levodopa; Movement Disorders; Neurons; Neurosurgical Procedures; Oxidopamine; Parkinson Disease; Treatment Failure | 2004 |
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
Topics: Apomorphine; Benzophenones; Cabergoline; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Ergolines; Humans; Levodopa; Movement Disorders; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2005 |
Novel pharmacological strategies for motor complications in Parkinson's disease.
Topics: Administration, Cutaneous; Animals; Antiparkinson Agents; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Dopamine Agonists; Drug Delivery Systems; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Indans; Levodopa; Liposomes; Monoamine Oxidase Inhibitors; Motor Neurons; Movement Disorders; Nitriles; Parkinson Disease; Receptors, Glutamate; Signal Transduction | 2005 |
Progress in clinical neurosciences: a forum on the early management of Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Magnetic Resonance Imaging; Movement Disorders; Parkinson Disease | 2005 |
Hyperhomocysteinemia in movement disorders: Current evidence and hypotheses.
Topics: Adolescent; Adult; Animals; Case-Control Studies; Catechol O-Methyltransferase; Cystathionine beta-Synthase; Dopamine Agents; Dystonia; Homocysteine; Humans; Huntington Disease; Hyperhomocysteinemia; Levodopa; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Movement Disorders; Parkinson Disease; Prospective Studies | 2006 |
Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
Topics: Animals; Brain; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement Disorders; Neuronal Plasticity; Neurons; Parkinson Disease | 2007 |
Paradoxes of functional neurosurgery: clues from basal ganglia recordings.
Topics: Antiparkinson Agents; Basal Ganglia; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Dystonia; Essential Tremor; Globus Pallidus; Humans; Levodopa; Movement Disorders; Neurosurgical Procedures; Parkinson Disease | 2008 |
Management of motor complications in advanced Parkinson's disease.
Topics: Combined Modality Therapy; Corpus Striatum; Deep Brain Stimulation; Dopamine Agonists; Dose-Response Relationship, Drug; Fetal Stem Cells; Humans; Levodopa; Movement Disorders; Neurosurgical Procedures; Parkinson Disease; Quality of Life; Receptors, Dopamine; Substantia Nigra; Thalamus | 2007 |
Involuntary movement disorders.
Topics: Brain; Chorea; Dyskinesia, Drug-Induced; Dystonia Musculorum Deformans; Humans; Huntington Disease; Levodopa; Meige Syndrome; Movement Disorders; Parasympatholytics; Parkinson Disease | 1984 |
A review of clinical trials of lithium in neurology.
Topics: Clinical Trials as Topic; Cluster Headache; Dyskinesia, Drug-Induced; Epilepsy; Headache; Humans; Huntington Disease; Hyperkinesis; Levodopa; Lithium; Meniere Disease; Migraine Disorders; Movement Disorders; Nervous System Diseases; Neurocognitive Disorders; Parkinson Disease; Sleep Wake Disorders; Torticollis | 1984 |
GABA system, GABA receptor agonists and dyskinesia.
Topics: Basal Ganglia; Cholinergic Fibers; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Huntington Disease; Levodopa; Movement Disorders; Receptors, Cell Surface; Receptors, GABA-A | 1983 |
[Dyskinesia (author's transl)].
Topics: Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Humans; Hyperkinesis; Hypersensitivity, Delayed; Levodopa; Movement Disorders; Psychotropic Drugs | 1980 |
[Biochemical aspects of involuntary movements (author's transl)].
Topics: Adenosine Triphosphate; Brain; Calcium; Dopamine; gamma-Aminobutyric Acid; Humans; Levodopa; Movement Disorders; Norepinephrine; Parkinson Disease; Serotonin | 1981 |
Positron emission tomography and central neurotransmitter systems in movement disorders.
Topics: Basal Ganglia; Dopamine; Humans; Huntington Disease; Levodopa; Movement Disorders; Parkinson Disease; Receptors, Dopamine; Receptors, GABA-A; Receptors, Opioid; Tomography, Emission-Computed; Tourette Syndrome | 1994 |
Parkinson's disease.
Topics: Cognition Disorders; Disabled Persons; Gait; Humans; Levodopa; Medical Audit; Movement Disorders; Neurocognitive Disorders; Neurosurgery; Parkinson Disease; Postural Balance; Practice Guidelines as Topic; Speech Disorders | 1994 |
Positron emission tomography: applications to the investigation of movement disorders.
Topics: Cerebrovascular Circulation; Humans; Levodopa; Movement; Movement Disorders; Parkinson Disease; Supranuclear Palsy, Progressive; Tomography, Emission-Computed | 1994 |
Three types of akinesia in the progressive course of Parkinson's disease.
Topics: Brain Mapping; Corpus Striatum; Dopamine; Dopamine Agents; Droxidopa; Globus Pallidus; Humans; Levodopa; Movement Disorders; Neural Pathways; Parkinson Disease; Receptors, Dopamine; Thalamic Nuclei | 1993 |
[Festination and freezing].
Topics: Gait; Humans; Levodopa; Movement Disorders; Supranuclear Palsy, Progressive | 1993 |
[Oral dyskinesis, facial dystonia].
Topics: Dyskinesia, Drug-Induced; Dystonia; Face; Female; Humans; Levodopa; Male; Meige Syndrome; Mouth; Movement Disorders; Receptors, Dopamine D1; Sulpiride; Tiapamil Hydrochloride; Trihexyphenidyl | 1993 |
The syndrome of gait ignition failure: a report of six cases.
Topics: Aged; Benserazide; Brain; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Female; Gait; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Neurologic Examination; Parkinson Disease; Syndrome; Tomography, X-Ray Computed | 1993 |
Nosological concept of juvenile parkinsonism with reference to the dopa-responsive syndrome.
Topics: Activities of Daily Living; Adolescent; Adult; Brain; Diagnosis, Differential; Female; Humans; Levodopa; Male; Movement Disorders; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary | 1993 |
Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia?
Topics: Animals; Corpus Striatum; Levodopa; Movement Disorders; Receptors, Dopamine | 1995 |
The neural mechanisms and progressive nature of symptoms of Parkinson's disease--based on clinical, neurophysiological and morphological studies.
Topics: Dihydroxyphenylalanine; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement Disorders; Nervous System; Parkinson Disease | 1995 |
Motor fluctuations in levodopa treatment: clinical pharmacology.
Topics: Antiparkinson Agents; Dopamine Agents; Humans; Levodopa; Movement Disorders; Parkinson Disease; Psychomotor Performance; Treatment Outcome | 1996 |
Management of motor fluctuations in Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agents; Drug Tolerance; Humans; Levodopa; Movement Disorders; Parkinson Disease; Psychomotor Performance; Treatment Outcome | 1996 |
Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias.
Topics: Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Globus Pallidus; Humans; Levodopa; Mental Disorders; Movement Disorders; Parkinson Disease; Sleep Wake Disorders; Stereotaxic Techniques; Thalamus | 1997 |
Problems with current pharmacologic treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Cognition Disorders; Disease Progression; Humans; Levodopa; Movement Disorders; Parkinson Disease; Posture | 1997 |
The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine Agonists; Drug Tolerance; Female; Humans; Levodopa; Male; Movement Disorders; Neurons; Parkinson Disease; Rats; Receptors, Dopamine; Receptors, GABA; Signal Transduction; Synaptic Transmission | 1998 |
[Periodic limb movement disorder].
Topics: Anticonvulsants; Clonazepam; Diagnosis, Differential; Dopamine Agents; Humans; Levodopa; Movement Disorders; Periodicity; Polysomnography; Restless Legs Syndrome; Sleep Wake Disorders | 1998 |
Motor fluctuations in Parkinson's disease: pathophysiology and treatment.
Topics: Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease | 1999 |
Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa.
Topics: Antiparkinson Agents; Humans; Levodopa; Movement Disorders; Parkinson Disease | 1999 |
Treating and preventing levodopa-induced dyskinesias: current and future strategies.
Topics: Clinical Trials as Topic; Dopamine Agonists; Forecasting; Levodopa; Movement Disorders; Polypharmacy; Receptors, Dopamine D2; Selegiline | 1999 |
Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Movement Disorders; Parkinson Disease | 2000 |
Restorative neurology in movement disorders.
Topics: Adrenal Medulla; Antiparkinson Agents; Brain; Cerebrovascular Circulation; Corpus Striatum; Fetal Tissue Transplantation; Graft Survival; Humans; Levodopa; Movement Disorders; Neurons; Parkinson Disease; Transplantation, Autologous | 2000 |
[Treatment of Parkinsonism: collaboration between the physician and the neurologist].
Topics: Aged; Antiparkinson Agents; Diagnosis, Differential; Drug Tolerance; Humans; Levodopa; Movement Disorders; Parkinsonian Disorders; Patient Care Team | 2000 |
Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.
Topics: Catechol O-Methyltransferase Inhibitors; Drug Therapy, Combination; Humans; Levodopa; Movement Disorders; Parkinson Disease; Receptors, Dopamine | 2000 |
Use of selective thalamotomy for various kinds of movement disorder, based on basic studies.
Topics: Antiparkinson Agents; Cerebral Hemorrhage; Chorea; Dyskinesia, Drug-Induced; Dyskinesias; Dystonia; Electrodes, Implanted; Electroencephalography; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Movement Disorders; Muscle Rigidity; Paresthesia; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques; Surgery, Computer-Assisted; Thalamic Nuclei; Tomography, X-Ray Computed; Treatment Outcome; Tremor | 2000 |
Catecholamines and neurologic diseases (second of two parts).
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Brain Diseases; Catecholamines; Cerebrovascular Disorders; Dopamine; Dysautonomia, Familial; Dystonia Musculorum Deformans; Hepatic Encephalopathy; Homovanillic Acid; Humans; Huntington Disease; Levodopa; Movement Disorders; Multiple Sclerosis; Nervous System Diseases; Parkinson Disease; Phenylketonurias; Seizures; Spinal Cord Injuries; Torticollis; Tourette Syndrome | 1975 |
The neuropharmacology of abnormal involuntary movement disorders (the dyskinesias).
Topics: Acetylcholine; Animals; Biogenic Amines; Brain; Brain Chemistry; Butyrophenones; Corpus Striatum; Dopamine; Dystonia Musculorum Deformans; Humans; Huntington Disease; Levodopa; Movement Disorders; Parkinson Disease; Parkinson Disease, Secondary; Phenothiazines; Serotonin; Tourette Syndrome; Tranquilizing Agents | 1975 |
Amine precursors in neurologic disorders and the psychoses.
Topics: Acetylcholine; Corpus Striatum; Dopamine; Homovanillic Acid; Humans; Huntington Disease; Hydroxyindoleacetic Acid; Levodopa; Movement Disorders; Nerve Degeneration; Parkinson Disease; Psychoses, Substance-Induced; Psychotic Disorders | 1975 |
The pharmacology of choreatic movement disorders.
Topics: Acetylcholine; Acute Disease; Amphetamine; Chorea; Dopamine; gamma-Aminobutyric Acid; Hepatolenticular Degeneration; Humans; Huntington Disease; Hyperthyroidism; Levodopa; Lupus Erythematosus, Systemic; Movement Disorders; Serotonin | 1976 |
Deanol in the management of involuntary movement disorders: a review.
Topics: Acetylcholine; Deanol; Dopamine; Dyskinesia, Drug-Induced; Ethanolamines; Female; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Models, Neurological; Movement Disorders; Parkinson Disease; Physostigmine; Research Design; Time Factors | 1977 |
The pathogensis and medical treatment of extrapyramidal disease.
Topics: Adult; Athetosis; Basal Ganglia Diseases; Caudate Nucleus; Chorea; Corpus Striatum; Dopamine; Dopamine Antagonists; Drug Administration Schedule; Dystonia; Female; gamma-Aminobutyric Acid; Glutamates; Haloperidol; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Tic Disorders | 1979 |
[Duality of dopaminergic receptors. Pharmacologic and clinical perspectives].
Topics: Animals; Apomorphine; Benzamides; Chorea; Fluorescent Antibody Technique; Guinea Pigs; Haloperidol; Humans; Levodopa; Movement Disorders; Parkinson Disease; Rats; Receptors, Dopamine | 1978 |
On the role of dopamine in the pathophysiology of anorexia nervosa.
Topics: 17-Ketosteroids; Amphetamine; Anorexia Nervosa; Apomorphine; Compulsive Personality Disorder; Dopamine; Female; Glucose Tolerance Test; Gonadotropins, Pituitary; Humans; Levodopa; Luteinizing Hormone; Male; Movement Disorders; Parkinson Disease; Schizophrenia; Steroids; Thinness | 1976 |
[The current treatment of Parkinson's disease].
Topics: Amantadine; Antidepressive Agents, Tricyclic; Dihydroxyphenylalanine; Drug Combinations; Histamine Antagonists; Humans; Levodopa; Mental Disorders; Movement Disorders; Neurosecretory Systems; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities; Pyridoxine; Stereotaxic Techniques | 1976 |
Physiopathology of experimental Parkinsonism in the monkey.
Topics: Animals; Cerebellum; Corpus Striatum; Disease Models, Animal; Dopamine; Haplorhini; Levodopa; Motor Cortex; Movement Disorders; Muscle Rigidity; Neural Pathways; Olivary Nucleus; Parkinson Disease, Secondary; Red Nucleus; Substantia Nigra; Tremor | 1975 |
Monkeys with nigrostriatal lesions effects of monoaminergic drugs.
Topics: Amino Acids; Animals; Antiparkinson Agents; Apomorphine; Biogenic Amines; Carboxy-Lyases; Catechol O-Methyltransferase Inhibitors; Chlorocebus aethiops; Corpus Striatum; Drug Interactions; Haplorhini; Harmaline; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Substantia Nigra; Tremor | 1976 |
Drug-induced dyskinesia in monkeys.
Topics: Amphetamine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Azides; Carbachol; Caudate Nucleus; Chlorpromazine; Disease Models, Animal; Dronabinol; Hydroxydopamines; Levodopa; Movement Disorders; Phenothiazines; Primates; Stereotaxic Techniques; Substantia Nigra; Tegmentum Mesencephali | 1975 |
Treatment of hyperkinetic movement disorders.
Topics: Benzodiazepines; Clonidine; Dystonia; Humans; Levodopa; Movement Disorders | 1990 |
Acute dystonia induced by neuroleptic drugs.
Topics: Acute Disease; alpha-Methyltyrosine; Animals; Antipsychotic Agents; Brain; Chlorpromazine; Disease Models, Animal; Drug Synergism; Dystonia; Fluphenazine; Haloperidol; Histamine H1 Antagonists; Levodopa; Mastication; Methyltyrosines; Movement Disorders; Parasympatholytics; Physostigmine; Primates; Rats | 1986 |
MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Deoxyglucose; Haplorhini; Humans; Levodopa; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Spiperone | 1987 |
'On-off' phenomenon: description, incidence and management.
Topics: Bromocriptine; Dose-Response Relationship, Drug; Humans; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Selegiline | 1987 |
Positron emission tomography in movement disorders.
Topics: Brain; Cerebrovascular Circulation; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Dystonia; Glucose; Humans; Huntington Disease; Levodopa; Movement Disorders; Oxygen Consumption; Parkinson Disease; Synapses; Tomography, Emission-Computed | 1985 |
On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics.
Topics: Blood-Brain Barrier; Dose-Response Relationship, Drug; Levodopa; Movement Disorders; Parkinson Disease | 1987 |
Drug treatment of hyperkinetic movement disorders.
Topics: Benzodiazepines; Botulinum Toxins; Dopamine; Dyskinesia, Drug-Induced; Humans; Hyperkinesis; Levodopa; Movement Disorders; Parasympathomimetics | 1987 |
Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment.
Topics: Corpus Striatum; Dopamine; Humans; Levodopa; Movement Disorders; Parkinson Disease; Receptors, Dopamine | 1986 |
Long-term use of dopamine agonists in Parkinson's disease.
Topics: Bromocriptine; Corpus Striatum; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Movement Disorders; Parkinson Disease; Pergolide; Receptors, Dopamine; Time Factors | 1985 |
The clinical physiology of side effects in long-term L-DOPA therapy.
Topics: Acetylcholine; Basal Ganglia; Brain Chemistry; Brain Stem; Creatinine; Diagnosis, Differential; Dopamine; gamma-Aminobutyric Acid; Humans; Hypothalamus; Levodopa; Movement Disorders; Norepinephrine; Parkinson Disease; Potassium; Receptors, Drug; Serotonin; Sodium; Time Factors | 1974 |
Nervous mechanisms involved in experimentally induced extrapyramidal disturbances.
Topics: Animals; Basal Ganglia Diseases; Benztropine; Brain; Cats; Caudate Nucleus; Cerebellar Nuclei; Chlorpromazine; Corpus Striatum; Disease Models, Animal; Dopamine; Haloperidol; Haplorhini; Humans; Levodopa; Movement Disorders; Olivary Nucleus; Parkinson Disease; Putamen; Rats; Red Nucleus; Substantia Nigra; Thalamic Nuclei; Tremor | 1974 |
Amantadine.
Topics: Acetylcholine; Amantadine; Animals; Antiviral Agents; Basal Ganglia Diseases; Behavior, Animal; Catecholamines; Chemical Phenomena; Chemistry; Dogs; Dopamine; Electroencephalography; Guinea Pigs; Haplorhini; Hemodynamics; Humans; Kinetics; Levodopa; Mice; Movement Disorders; Parasympatholytics; Parkinson Disease; Rabbits; Rats; Serotonin; Virus Diseases | 1974 |
Parkinson's disease and levodopa. A five-year follow-up and review.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Animals; Athetosis; Basal Ganglia; Chorea; Corpus Striatum; Dementia; Depression; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Movement Disorders; Nausea; Parkinson Disease; Parkinson Disease, Postencephalitic; Sexual Behavior; Substantia Nigra; Vomiting | 1974 |
70 trial(s) available for levodopa and Movement Disorders
| Article | Year |
|---|---|
Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Chemotherapy, Adjuvant; Dopamine Agonists; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Quality of Life; Treatment Outcome | 2022 |
Stimulation of the pedunculopontine nucleus area in Parkinson's disease: effects on speech and intelligibility.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Data Interpretation, Statistical; Deep Brain Stimulation; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Preoperative Period; Prospective Studies; Psychomotor Performance; Respiration; Semantics; Speech; Speech Intelligibility; Subthalamic Nucleus | 2014 |
Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Depressive Disorder; Disease Progression; Duodenum; Female; Gait Disorders, Neurologic; Humans; Hyperkinesis; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Patient Satisfaction; Quality of Life; Sickness Impact Profile; Surveys and Questionnaires; Treatment Outcome | 2008 |
Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies.
Topics: Aged; Dopamine Agonists; Female; Follow-Up Studies; Hallucinations; Humans; Levodopa; Lewy Body Disease; Male; Mental Disorders; Movement Disorders | 2008 |
Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cohort Studies; Disability Evaluation; Disease Progression; Early Diagnosis; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Outcome Assessment, Health Care; Parkinson Disease; Pramipexole; Quality of Life; Time; Treatment Outcome | 2009 |
Botulinum toxin in the treatment of lingual movement disorders.
Topics: Aged; Anti-Dyskinesia Agents; Antiparkinson Agents; Botulinum Toxins; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Retrospective Studies; Time Factors; Tongue Diseases | 2009 |
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Case-Control Studies; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Risk Factors; Time Factors; Treatment Outcome | 2004 |
Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Case-Control Studies; Cognition Disorders; Cohort Studies; Dyskinesia, Drug-Induced; Female; Human Development; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Smoking; Time Factors | 2005 |
Extradural motor cortex stimulation (EMCS) for Parkinson's disease. History and first results by the study group of the Italian neurosurgical society.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Comorbidity; Deep Brain Stimulation; Dura Mater; Electrodes, Implanted; Female; Humans; Italy; Levodopa; Male; Middle Aged; Motor Cortex; Movement Disorders; Parkinson Disease; Pilot Projects; Prognosis; Recovery of Function; Risk Assessment; Treatment Outcome | 2005 |
Dopaminergic effects on encoding of a motor memory in chronic stroke.
Topics: Aged; Aged, 80 and over; Brain; Chronic Disease; Cross-Over Studies; Dopamine; Dopamine Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Levodopa; Male; Memory; Middle Aged; Motor Skills; Movement; Movement Disorders; Muscle, Skeletal; Neuronal Plasticity; Paresis; Recovery of Function; Stroke; Thumb; Treatment Outcome | 2005 |
Bimodal administration of entacapone in Parkinson's disease patients improves motor control.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Catechol O-Methyltransferase; Catechols; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Nitriles; Parkinson Disease; Severity of Illness Index | 2008 |
Greater motor improvement in right hemibody Parkinson's patients after dopaminergic medications.
Topics: Aged; Analysis of Variance; Carbidopa; Dopamine Agents; Female; Functional Laterality; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Movement Disorders; Neuropsychological Tests; Parkinson Disease | 2009 |
A review of clinical trials of lithium in neurology.
Topics: Clinical Trials as Topic; Cluster Headache; Dyskinesia, Drug-Induced; Epilepsy; Headache; Humans; Huntington Disease; Hyperkinesis; Levodopa; Lithium; Meniere Disease; Migraine Disorders; Movement Disorders; Nervous System Diseases; Neurocognitive Disorders; Parkinson Disease; Sleep Wake Disorders; Torticollis | 1984 |
On-off effects in Parkinson's disease: a controlled investigation of ascorbic acid therapy.
Topics: Aged; Ascorbic Acid; Clinical Trials as Topic; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1983 |
[A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
Topics: Adult; Aged; Benserazide; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1991 |
Levodopa failure in chronic manganism.
Topics: Adult; Chronic Disease; Double-Blind Method; Humans; Levodopa; Male; Manganese Poisoning; Middle Aged; Movement Disorders; Nervous System Diseases; Placebos | 1994 |
The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Prevalence; Prospective Studies; Severity of Illness Index; Survival Analysis; Treatment Failure | 1994 |
Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
Topics: Antiparkinson Agents; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Movement Disorders; Muscle Rigidity; Neurologic Examination; Parkinson Disease | 1993 |
Apomorphine and lisuride infusion. A comparative chronic study.
Topics: Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Levodopa; Lisuride; Long-Term Care; Middle Aged; Movement Disorders; Neurologic Examination; Parkinson Disease | 1993 |
A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Indoles; Levodopa; Movement Disorders; Parkinson Disease; Receptors, Dopamine D2 | 1996 |
An open study with reversible MAO-A inhibitors in complicated Parkinson's disease.
Topics: Antiparkinson Agents; Benzamides; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease | 1996 |
Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.
Topics: Adrenergic beta-Antagonists; Adult; Antiparkinson Agents; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Propranolol; Prospective Studies; Treatment Outcome | 1996 |
Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Movement Disorders; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 1995 |
Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect.
Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1996 |
Age at onset: the major determinant of outcome in Parkinson's disease.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Bromocriptine; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Postural Balance; Treatment Outcome; Tremor | 1995 |
Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa.
Topics: Aged; Carbidopa; Circadian Rhythm; Cross-Over Studies; Delayed-Action Preparations; Dihydroxyphenylalanine; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1996 |
Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation.
Topics: Adult; Aged; Carbidopa; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders | 1996 |
Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Placebos; Prospective Studies | 1997 |
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Selegiline | 1997 |
Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Placebos; Severity of Illness Index | 1997 |
Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease.
Topics: Antiparkinson Agents; Electric Stimulation Therapy; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Thalamic Nuclei; Thalamus; Treatment Outcome | 1997 |
Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
Topics: Activities of Daily Living; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1998 |
Opposite motor effects of pallidal stimulation in Parkinson's disease.
Topics: Apomorphine; Electric Stimulation Therapy; Electrodes, Implanted; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Parkinson Disease; Stereotaxic Techniques; Treatment Outcome | 1998 |
Does pattern electroretinogram spatial tuning alteration in Parkinson's disease depend on motor disturbances or retinal dopaminergic loss?
Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Brain Injuries; Dopamine; Electroencephalography; Electroretinography; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Pattern Recognition, Visual; Photic Stimulation; Retina; Space Perception; Vision, Monocular | 1998 |
Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Prospective Studies | 1998 |
Alpha-dihydroergocryptine in Parkinson's disease: a multicentre randomized double blind parallel group study.
Topics: Aged; Antiparkinson Agents; Dihydroergotoxine; Disabled Persons; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Movement Disorders; Parkinson Disease; Treatment Outcome | 1999 |
Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles | 1999 |
Impairment of EEG desynchronisation before and during movement and its relation to bradykinesia in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Basal Ganglia; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Movement; Movement Disorders; Parkinson Disease; Prefrontal Cortex | 1999 |
Motor fluctuations in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Movement; Movement Disorders; Parkinson Disease; Risk Factors | 1999 |
Treatment of periodic leg movements with a dopaminergic agonist in subjects with total spinal cord lesions.
Topics: Adult; Benserazide; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Humans; Levodopa; Male; Movement Disorders; Nocturnal Paroxysmal Dystonia; Paraplegia; Polysomnography; Restless Legs Syndrome | 1999 |
Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease.
Topics: Administration, Oral; Amantadine; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Levodopa; Male; Medical Records; Middle Aged; Movement Disorders; Parkinson Disease; Safety; Severity of Illness Index; Treatment Outcome | 2000 |
Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Pressure; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Nausea; Parkinson Disease; Vomiting | 1975 |
Deprenyl in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Phenethylamines | 1977 |
Studies on the anti-dyskinesia effect of apomorphine in man.
Topics: Administration, Oral; Adult; Aged; Apomorphine; Clinical Trials as Topic; Drug Evaluation; Female; Haloperidol; Humans; Huntington Disease; Injections, Intravenous; Levodopa; Male; Middle Aged; Movement Disorders | 1976 |
[Treatment of parkinsonian syndromes by bromocriptin].
Topics: Aged; Amantadine; Bromocriptine; Clinical Trials as Topic; Drug Evaluation; Ergolines; Female; Humans; Hypotension; Levodopa; Male; Movement Disorders; Nausea; Parkinson Disease, Secondary | 1977 |
Experiences with L-deprenyl in Parkinsonism.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1978 |
Meige disease: striatal dopaminergic preponderance.
Topics: Aged; Apomorphine; Basal Ganglia; Blepharospasm; Clinical Trials as Topic; Diagnosis, Differential; Eyelid Diseases; Facial Muscles; Female; Haloperidol; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Physostigmine; Placebos | 1979 |
Madopar versus sinemet. A clinical study on their effectiveness.
Topics: Adult; Aged; Benserazide; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Serine | 1975 |
Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Metoclopramide; Middle Aged; Movement Disorders; Nausea; Parkinson Disease; Parkinson Disease, Secondary; Pimozide; Placebos; Promethazine | 1975 |
Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Mental Disorders; Middle Aged; Movement Disorders; Parkinson Disease | 1975 |
Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.
Topics: Administration, Oral; Aged; Apomorphine; Carbidopa; Clinical Trials as Topic; Drug Therapy, Combination; Female; Growth Hormone; Humans; Kidney; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Secretory Rate | 1976 |
Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease: two years of follow-up.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1990 |
Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Movement Disorders; Multicenter Studies as Topic; Parkinson Disease; Randomized Controlled Trials as Topic | 1989 |
[Clinical study on the treatment of dyskinesia by L-stepholidine].
Topics: Aged; Berberine; Berberine Alkaloids; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Multicenter Studies as Topic; Tourette Syndrome | 1989 |
Double-blind carbidopa/levodopa and placebo study in tardive dyskinesia.
Topics: Adult; Aged; Antipsychotic Agents; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Psychiatric Status Rating Scales; Random Allocation | 1988 |
Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study.
Topics: Benserazide; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Periodicity; Reaction Time; Restless Legs Syndrome; Sleep; Surveys and Questionnaires | 1988 |
R-(-)-deprenyl in the treatment of end-of-dose akinesia.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1987 |
Clinical trial of Madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy.
Topics: Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1987 |
Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Open clinical study of Madopar HBS.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Infant, Newborn; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Treatment of parkinsonian conditions with a controlled-release form of levodopa--preliminary study.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Preliminary experience with Madopar HBS: clinical observations and plasma levodopa concentrations.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Female; Follow-Up Studies; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
Topics: Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Hospitalization; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.
Topics: Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1987 |
Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Ergolines; Gait; Humans; Levodopa; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Pergolide; Random Allocation | 1985 |
Caerulein treatment of Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Ceruletide; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1985 |
Motor function in the normal aging population: treatment with levodopa.
Topics: Aged; Aging; Carbidopa; Dopamine; Drug Combinations; Humans; Levodopa; Middle Aged; Movement; Movement Disorders; Parkinson Disease | 1985 |
L-alpha-methyldopa hydrazine (Carbidopa) combined with L-dopa in the treatment of Parkinson's disease.
Topics: Aged; Blood Pressure; Carbidopa; Clinical Trials as Topic; Depression, Chemical; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Nausea; Parkinson Disease; Placebos; Posture; Vomiting | 1974 |
[Levodopa as a single treatment of Parkinsonism. Long-term control of 24 cases with discrimination analysis].
Topics: Adult; Aged; Clinical Trials as Topic; Drug Evaluation; Female; Follow-Up Studies; Humans; Levodopa; Male; Methods; Middle Aged; Movement Disorders; Muscle Rigidity; Parkinson Disease; Pyramidal Tracts; Time Factors; Tremor | 1974 |
Piribedil in Parkinsonism.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Confusion; Drug Evaluation; Drug Therapy, Combination; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease | 1974 |
341 other study(ies) available for levodopa and Movement Disorders
| Article | Year |
|---|---|
[Abnormal posture of the trunk related to donepezil hydrochloride: report of 2 cases].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Levodopa; Male; Movement Disorders; Piperidines; Posture | 2023 |
Cytosolic non-vesicular dopamine accumulation as the predominant mechanism for developing non-DOPA responsive parkinsonism in late-stage Huntington disease.
Topics: Animals; Calcium; Corpus Striatum; Disease Progression; Dopamine; Humans; Huntington Disease; Levodopa; Mitochondria; Movement; Movement Disorders; Neurotransmitter Agents; Parkinsonian Disorders | 2019 |
Neuroimaging evaluation and successful treatment by using directional deep brain stimulation and levodopa in a patient with GNAO1-associated movement disorder: A case report.
Topics: Deep Brain Stimulation; GTP-Binding Protein alpha Subunits, Gi-Go; Humans; Levodopa; Movement Disorders; Neuroimaging | 2020 |
Orofacial dystonia and asssociated bulbar symptoms in multiple system atrophy: A blinded video analysis.
Topics: Dystonia; Dystonic Disorders; Humans; Levodopa; Movement Disorders; Multiple System Atrophy | 2020 |
Forced exercise activates the NrF2 pathway in the striatum and ameliorates motor and behavioral manifestations of Parkinson's disease in rotenone-treated rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Gait Disorders, Neurologic; Levodopa; Male; Memory, Short-Term; Movement Disorders; Neostriatum; NF-E2-Related Factor 2; Parkinson Disease, Secondary; Physical Conditioning, Animal; Psychomotor Performance; Rats; Rats, Wistar; Rotenone; Signal Transduction; Tyrosine 3-Monooxygenase; Uncoupling Agents; Up-Regulation | 2020 |
[Progressive supranuclear paralysis with levodopa-induced dyskinesia].
Topics: Aged; Dyskinesias; Humans; Levodopa; Movement Disorders; Neurodegenerative Diseases; Supranuclear Palsy, Progressive | 2021 |
Treatment of Painless Legs and Moving Toes Syndrome Associated With Multiple System Atrophy With Levodopa.
Topics: Dopamine Agents; Female; Humans; Levodopa; Middle Aged; Movement Disorders; Multiple System Atrophy; Syndrome | 2021 |
Early-morning OFF and levodopa dose failures in patients with Parkinson's disease attending a routine clinical appointment using Time-to-ON Questionnaire.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Appointments and Schedules; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Pilot Projects; Surveys and Questionnaires; Treatment Failure | 2019 |
PDE10A mutation in two sisters with a hyperkinetic movement disorder - Response to levodopa.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Child; Consanguinity; Dopamine Agents; Drug Combinations; Epilepsy, Temporal Lobe; Exome Sequencing; Female; Humans; Hyperkinesis; Infant; Levodopa; Movement Disorders; Phosphoric Diester Hydrolases; Siblings | 2019 |
Chediak-Higashi syndrome presenting as young-onset levodopa-responsive parkinsonism.
Topics: Antiparkinson Agents; Chediak-Higashi Syndrome; Electromyography; Humans; Hyperpigmentation; Levodopa; Magnetic Resonance Imaging; Male; Movement Disorders; Mutation, Missense; Neurologic Examination; Parkinson Disease; Skin; Young Adult | 2013 |
Gray matter atrophy distinguishes between Parkinson disease motor subtypes.
Topics: Aged; Antiparkinson Agents; Atrophy; Brain; Cognition; Data Interpretation, Statistical; Female; Gait Disorders, Neurologic; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Nerve Net; Neural Pathways; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Risk Factors | 2013 |
Long-term outcome of young onset Parkinson's disease after subthalamic stimulation--a cross-sectional study.
Topics: Activities of Daily Living; Adult; Age of Onset; Antiparkinson Agents; Cognition; Cohort Studies; Cross-Sectional Studies; Deep Brain Stimulation; Female; Follow-Up Studies; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Movement Disorders; Parkinson Disease; Prognosis; Subthalamic Nucleus; Treatment Outcome | 2013 |
Relevance of EARLYSTIM in a tertiary movement disorders center.
Topics: Adolescent; Adult; Antiparkinson Agents; Deep Brain Stimulation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Quality of Life; Randomized Controlled Trials as Topic; Retrospective Studies; Young Adult | 2014 |
[Treatment & management guidelines 2011 for Parkinson disease].
Topics: Antiparkinson Agents; Cognition Disorders; Depression; Dopamine Agonists; Drug Administration Schedule; Humans; Japan; Levodopa; Movement Disorders; Neurology; Parkinson Disease; Practice Guidelines as Topic; Societies, Medical | 2013 |
Motor phenotypes, medication and mood: further associations with impulsive behaviours in Parkinson's disease.
Topics: Affect; Aged; Antiparkinson Agents; Cohort Studies; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenotype | 2014 |
Association between fatigue and other motor and non-motor symptoms in Parkinson's disease patients.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Fatigue; Female; Humans; Italy; Levodopa; Logistic Models; Male; Middle Aged; Movement Disorders; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Quality of Life | 2014 |
Neuropeptide S counteracts 6-OHDA-induced motor deficits in mice.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Area Under Curve; Disease Models, Animal; Dopamine Agents; Female; Levodopa; Mice; Movement Disorders; Oxidopamine; Receptors, G-Protein-Coupled; Rotarod Performance Test; Substantia Nigra; Tyrosine 3-Monooxygenase | 2014 |
Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Dyskinesia Agents; Cell Death; Cytosol; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Levodopa; Mesencephalon; Mice, Inbred C57BL; Mice, Transgenic; Motor Skills; Movement Disorders; Oxidative Stress; Parkinsonian Disorders; Vesicular Monoamine Transport Proteins | 2015 |
Non-motor fluctuations in Parkinson's disease: prevalence, characteristics and management in a large cohort of parkinsonian outpatients.
Topics: Age Factors; Aged; Antiparkinson Agents; Case Management; Cross-Sectional Studies; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Primary Dysautonomias | 2014 |
[Dyskinesia-hyperpyrexia syndrome in a patient with Parkinson's disease: a case report].
Topics: Aged; Benzothiazoles; Delayed-Action Preparations; Drug Substitution; Drug Therapy, Combination; Female; Fever; Humans; Levodopa; Movement Disorders; Parkinson Disease; Pramipexole; Selegiline | 2015 |
Cerebrospinal Fluid Monoamine Metabolite Analysis in Pediatric Movement Disorders.
Topics: Adolescent; Anti-Dyskinesia Agents; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Levodopa; Male; Movement Disorders; Neurotransmitter Agents; Young Adult | 2015 |
Sex-Related Prognostic Predictors for Parkinson Disease Undergoing Subthalamic Stimulation.
Topics: Antiparkinson Agents; Cognition; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Neuropsychological Tests; Parkinson Disease; Postoperative Complications; Prognosis; Retrospective Studies; Sex Characteristics; Subthalamic Nucleus; Treatment Outcome | 2015 |
[VALIDATION OF THE HUNGARIAN MDS-UPDRS: WHY DO WE NEED A NEW PARKINSON SCALE?].
Topics: Antiparkinson Agents; Cognition; Factor Analysis, Statistical; Humans; Hungary; Language; Levodopa; Movement Disorders; Observer Variation; Parkinson Disease; Reproducibility of Results; Severity of Illness Index; Surveys and Questionnaires; Translations; Tremor | 2014 |
Brain catecholamine depletion and motor impairment in a Th knock-in mouse with type B tyrosine hydroxylase deficiency.
Topics: Animals; Biopterins; Brain; Catecholamines; Disease Models, Animal; Dopamine Agents; Eating; Female; Gene Expression Regulation; Gene Knock-In Techniques; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Movement Disorders; Mutation; Thyroxine; Tyrosine 3-Monooxygenase | 2015 |
The preferential nNOS inhibitor 7-nitroindazole and the non-selective one N(G)-nitro-L-arginine methyl ester administered alone or jointly with L-DOPA differentially affect motor behavior and monoamine metabolism in sham-operated and 6-OHDA-lesioned rats.
Topics: Adrenergic Agents; Animals; Apomorphine; Biogenic Monoamines; Brain; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Indazoles; Levodopa; Locomotion; Male; Movement Disorders; Neuroprotective Agents; NG-Nitroarginine Methyl Ester; Oxidopamine; Rats; Rats, Wistar; Time Factors | 2015 |
Risk and course of motor complications in a population-based incident Parkinson's disease cohort.
Topics: Age Factors; Aged; Antiparkinson Agents; Cohort Studies; Disease Progression; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Incidence; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Movement Disorders; Norway; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Risk Factors; Sex Factors; Superior Sagittal Sinus | 2016 |
The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastric Bypass; Gels; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Quality of Life; Retrospective Studies; Romania | 2016 |
Increased sexual arousal in patients with movement disorders.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Deep Brain Stimulation; Dopamine Agents; Female; Humans; Impulsive Behavior; Levodopa; Libido; Male; Middle Aged; Movement Disorders; Prospective Studies; Sexual Behavior; Sexual Dysfunctions, Psychological; Young Adult | 2016 |
[Drugs for improvement of motor deficits after stroke].
Topics: Antibodies, Monoclonal; Combined Modality Therapy; Evidence-Based Medicine; Humans; Levodopa; Molecular Targeted Therapy; Movement Disorders; Neuromuscular Agents; Outcome Assessment, Health Care; Selective Serotonin Reuptake Inhibitors; Stem Cell Transplantation; Stroke Rehabilitation; Treatment Outcome | 2016 |
Levodopa, motor complications and disease progression.
Topics: Antiparkinson Agents; Disease Progression; Humans; Levodopa; Movement Disorders; Parkinson Disease | 2008 |
Response of motor complications in Cockayne syndrome to carbidopa-levodopa.
Topics: Adolescent; Carbidopa; Cockayne Syndrome; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Movement Disorders | 2008 |
[Patterns of neuronal activity in the basal ganglia nucleus in parkinsonian patients with levodopa-induced dyskinesia].
Topics: Adult; Aged; Basal Ganglia; Electrophysiology; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Neural Pathways; Neurons; Parkinson Disease; Subthalamic Nucleus | 2008 |
L-dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats.
Topics: Animals; Brain; Brain Chemistry; Corpus Striatum; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Movement Disorders; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Rotation; Serotonin; Sympatholytics; Tryptophan Hydroxylase | 2009 |
Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Dopamine Plasma Membrane Transport Proteins; Female; Follow-Up Studies; Humans; Iodine Radioisotopes; Levodopa; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease, Secondary; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tropanes | 2009 |
Multitracer assessment of dopamine function after transplantation of embryonic stem cell-derived neural stem cells in a primate model of Parkinson's disease.
Topics: Animals; Carbon Radioisotopes; Cells, Cultured; Cocaine; Disease Models, Animal; Dopamine; Dopamine Agents; Embryonic Stem Cells; Levodopa; Macaca fascicularis; Methamphetamine; Movement Disorders; Neurons; Parkinson Disease; Positron-Emission Tomography; Putamen; Raclopride; Tyrosine 3-Monooxygenase | 2009 |
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.
Topics: Age Factors; Animals; Antiparkinson Agents; Apomorphine; Brain; Chromosomes, Artificial, Bacterial; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Gene Transfer Techniques; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Mice; Mice, Transgenic; Movement Disorders; Mutation, Missense; Neurons; Nomifensine; Parkinson Disease; Protein Serine-Threonine Kinases | 2009 |
Medical treatment of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cognition Disorders; Corpus Striatum; Digestive System Physiological Phenomena; Dopamine Agonists; Enzyme Inhibitors; Humans; Hypotension, Orthostatic; Levodopa; Mental Disorders; Monoamine Oxidase Inhibitors; Motor Activity; Movement Disorders; Neurons; Parkinson Disease; Sleep Wake Disorders; Substantia Nigra | 2009 |
Onset and spread of dyskinesias and motor symptoms in Parkinson's disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Female; Functional Laterality; Hand Strength; Humans; Italy; Levodopa; Male; Middle Aged; Motor Skills; Movement; Movement Disorders; Parkinson Disease; Retrospective Studies | 2009 |
Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cognition Disorders; Comorbidity; Disability Evaluation; Dopamine Agonists; Female; Gastrointestinal Diseases; Humans; Indoles; Levodopa; Male; Memory Disorders; Middle Aged; Mood Disorders; Movement Disorders; Neurologic Examination; Nocturia; Outcome Assessment, Health Care; Parkinson Disease; Pramipexole; Prevalence; Restless Legs Syndrome; Treatment Outcome | 2009 |
Hemibody mirror movements in hemiparkinsonism-hemiatrophy syndrome.
Topics: Antiparkinson Agents; Arm; Electromyography; Facial Muscles; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Contraction; Muscle, Skeletal; Muscular Atrophy; Parkinsonian Disorders; Peripheral Nervous System Diseases; Syndrome; Treatment Outcome | 2009 |
Impaired awareness of movement disorders in Parkinson's disease.
Topics: Adult; Aged; Agnosia; Analysis of Variance; Antiparkinson Agents; Awareness; Female; Humans; Hypokinesia; Levodopa; Middle Aged; Movement Disorders; Neuropsychological Tests; Parkinson Disease; Self Concept; Statistics, Nonparametric | 2010 |
Adjunct treatment with levodopa in a patient with dementia with Lewy bodies, delusions and severe neuroleptic hypersensitivity syndrome: some comments.
Topics: Antiparkinson Agents; Clozapine; Delusions; Drug Therapy, Combination; Humans; Levodopa; Lewy Body Disease; Movement Disorders; Neuroleptic Malignant Syndrome; Severity of Illness Index | 2010 |
The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Callithrix; Carbidopa; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Female; Levodopa; Male; Methyldopa; Motor Activity; Movement Disorders | 2010 |
Dopamine-dependent motor learning: insight into levodopa's long-duration response.
Topics: Animals; Behavior, Animal; Benzazepines; Dopamine; Dopamine Agents; Homeodomain Proteins; Learning; Levodopa; Mice; Mice, Knockout; Motor Skills; Movement Disorders; Reaction Time; Rotarod Performance Test; Time Factors; Transcription Factors | 2010 |
The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Area Under Curve; Benzoxazoles; Callithrix; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Motor Activity; Movement Disorders; Piperazines; Statistics, Nonparametric; Time Factors | 2010 |
Decision making under risk condition in patients with Parkinson's disease: a behavioural and fMRI study.
Topics: Aged; Antiparkinson Agents; Behavior; Decision Making; Dopamine Agonists; Feedback, Psychological; Female; Gambling; Games, Experimental; Gyrus Cinguli; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Memory; Movement Disorders; Neuropsychological Tests; Oxygen; Parkinson Disease; Photic Stimulation; Psychomotor Performance; Risk-Taking | 2010 |
Urinary 8-hydroxydeoxyguanosine correlate with hallucinations rather than motor symptoms in Parkinson's disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Deoxyguanosine; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Neuropsychological Tests; Oxidative Stress; Parkinson Disease; Reference Values | 2011 |
Deletion in the tyrosine hydroxylase gene in a patient with a mild phenotype.
Topics: Antiparkinson Agents; Carbidopa; DNA Mutational Analysis; Drug Combinations; Female; Homovanillic Acid; Humans; Infant; Levodopa; Movement Disorders; Phenotype; Sequence Deletion; Tyrosine 3-Monooxygenase; Video Recording | 2011 |
Feeling of presence in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Perceptual Disorders; Psychotic Disorders; Surveys and Questionnaires | 2011 |
Tardive syndrome and Parkinson's disease responsive to concomitant tetrabenazine and levodopa therapy.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Depression; Female; Flupenthixol; Humans; Levodopa; Movement Disorders; Parkinson Disease; Tetrabenazine | 2011 |
Reduced serum caeruloplasmin levels in non-wilsonian movement disorders.
Topics: Adult; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Ceruloplasmin; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Regression Analysis; Retrospective Studies | 2011 |
Chronic 5-HT transporter blockade reduces DA signaling to elicit basal ganglia dysfunction.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Animals, Newborn; Basal Ganglia; Cell Count; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Exploratory Behavior; Fluoxetine; Homovanillic Acid; Levodopa; Male; Mice; Mice, Transgenic; Movement Disorders; Psychomotor Performance; Random Allocation; Rotarod Performance Test; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Signal Transduction; Substantia Nigra; Ventral Tegmental Area | 2011 |
Child neurology: paroxysmal stiffening, upward gaze, and hypotonia: hallmarks of sepiapterin reductase deficiency.
Topics: 5-Hydroxytryptophan; Alcohol Oxidoreductases; Behavior; Benserazide; Consanguinity; Developmental Disabilities; Dopamine Agents; Drug Combinations; Eye Movements; Female; Humans; Infant; Levodopa; Movement Disorders; Muscle Hypotonia; Nervous System Diseases; Neurotransmitter Agents; Phenylketonurias; Treatment Outcome | 2012 |
Use of electroconvulsive therapy in Parkinson disease with residual axial symptoms partially unresponsive to L-dopa: a pilot study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Drug Resistance; Electroconvulsive Therapy; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Pilot Projects; Prospective Studies; Quality of Life; Surveys and Questionnaires; Treatment Outcome; Walking | 2012 |
Paroxysmal tonic upgaze in normal children: a case series and a review of the literature.
Topics: Adolescent; Age of Onset; Child; Child, Preschool; Dopamine Agents; Epilepsy, Generalized; Eye Movements; Female; Follow-Up Studies; Humans; Levodopa; Male; Movement Disorders; Seizures; Seizures, Febrile; Stress, Psychological | 2012 |
Profile of multiple system atrophy in Moroccan patients attending a movement disorders outpatient clinic in Rabat university hospital.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Amantadine; Disease Progression; Dopamine Agonists; Female; Hospitals, University; Humans; Hypotension, Orthostatic; Levodopa; Magnetic Resonance Imaging; Male; Mental Disorders; Middle Aged; Morocco; Movement Disorders; Multiple System Atrophy; Outpatient Clinics, Hospital; Phenotype; Retrospective Studies; Sleep Disorders, Intrinsic; Symptom Assessment; Urination Disorders | 2013 |
NMDA receptor genotypes associated with the vulnerability to develop dyskinesia.
Topics: Age of Onset; Alleles; Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dyskinesias; Gene Expression; Genetic Predisposition to Disease; Genotype; Humans; Huntington Disease; Levodopa; Long-Term Care; Motor Cortex; Movement Disorders; Polymorphism, Single Nucleotide; Receptors, N-Methyl-D-Aspartate; Schizophrenia | 2012 |
Loss of Mfn2 results in progressive, retrograde degeneration of dopaminergic neurons in the nigrostriatal circuit.
Topics: Animals; Biological Transport; Corpus Striatum; Dopaminergic Neurons; Female; Gene Deletion; Growth Charts; GTP Phosphohydrolases; Levodopa; Male; Mice; Mice, Knockout; Mitochondria; Motor Activity; Movement Disorders; Phenotype; Retrograde Degeneration | 2012 |
Clinical features and varieties of non-motor fluctuations in Parkinson's disease: a Japanese multicenter study.
Topics: Aged; Aged, 80 and over; Asian People; Cross-Sectional Studies; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Surveys and Questionnaires | 2013 |
Continuous buccolingual masticatory dyskinesia in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Mastication; Movement Disorders; Parkinson Disease; Pergolide | 2012 |
The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzodioxoles; Biogenic Monoamines; Callithrix; Dose-Response Relationship, Drug; Female; Levodopa; Methylamines; Motor Activity; Movement Disorders; Neurotransmitter Uptake Inhibitors | 2012 |
Eppendorf finalist. Striatal interneurons: causes of or cures for movement disorders?
Topics: Adamantane; Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Humans; Interneurons; Levodopa; Mice; Mice, Transgenic; Movement Disorders; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Receptors, AMPA; Receptors, Kainic Acid; Treatment Failure | 2012 |
Decreased phasic EMG activity during rapid eye movement sleep in treatment-naïve Parkinson's disease: effects of treatment with levodopa and progression of illness.
Topics: Aged; Dopamine Agonists; Electromyography; Female; Humans; Levodopa; Male; Movement Disorders; Muscle Tonus; Parkinson Disease; Severity of Illness Index; Sleep, REM | 2002 |
Non-oral drug delivery in Parkinson's disease: a summary from the symposium at the 7th International Congress of Parkinson's Disease and Movement Disorders. 10-14 November 2002, Miami, FL, USA.
Topics: Antiparkinson Agents; Congresses as Topic; Humans; Intestinal Absorption; Levodopa; Movement Disorders; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2003 |
Relationship between freezing of gait (FOG) and other features of Parkinson's: FOG is not correlated with bradykinesia.
Topics: Antiparkinson Agents; Gait Ataxia; Gait Disorders, Neurologic; Humans; Hypokinesia; Levodopa; Motor Activity; Movement Disorders; Parkinson Disease; Postural Balance; Speech Disorders; Tremor | 2003 |
[ON THE CONTROL OF AKINESIA AND OTHER EXTRAPYRAMIDAL MOTOR DISORDERS WITH L-DOPA (L-DIHYDROXYPHENYLALANINE)].
Topics: Chorea; Dihydroxyphenylalanine; Electromyography; Extrapyramidal Tracts; Humans; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Neurosurgery; Neurosurgical Procedures; Parkinsonian Disorders; Stereotaxic Techniques; Torticollis; Tremor | 1964 |
Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders.
Topics: Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Cross-Sectional Studies; Demography; Diagnosis, Differential; Ethnicity; Europe; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Neurologic Examination; Outpatient Clinics, Hospital; Parkinsonian Disorders; Prevalence; Prospective Studies; Referral and Consultation; Retrospective Studies; Statistics, Nonparametric | 2003 |
Split spinal cord malformation in an elderly patient: case report.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Carbidopa; Clonazepam; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Low Back Pain; Magnetic Resonance Imaging; Movement Disorders; Spinal Dysraphism; Tomography, X-Ray Computed | 2004 |
Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy).
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesias; Forelimb; Image Processing, Computer-Assisted; Levodopa; Male; Movement Disorders; Parkinson Disease; Rats; Striatonigral Degeneration | 2004 |
Impact of the motor complications of Parkinson's disease on the quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Health Status Indicators; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Neurologic Examination; Parkinson Disease; Psychiatric Status Rating Scales; Quality of Life; Retrospective Studies; Surveys and Questionnaires | 2005 |
Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Bromocriptine; Dementia; Disease Progression; Dose-Response Relationship, Drug; Employment; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Mortality; Movement Disorders; Multicenter Studies as Topic; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Time Factors | 2005 |
Does L-dopa treatment contribute to reduction in body weight in elderly patients with Parkinson's disease?
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Deglutition Disorders; Female; Follow-Up Studies; Humans; Levodopa; Male; Motor Activity; Movement Disorders; Nausea; Parkinson Disease; Smell; Weight Loss | 2005 |
[Cognitive dysfunction in patients with Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Cholinergic Antagonists; Cognition Disorders; Dementia; Dopamine Agonists; Female; Frontal Lobe; Functional Laterality; Hippocampus; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Movement Disorders; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index | 2005 |
Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.
Topics: Activities of Daily Living; Adult; Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Cognition; Cognition Disorders; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Movement Disorders; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires | 2005 |
Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Denervation; Glutamic Acid; Levodopa; Male; Movement Disorders; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Subthalamic Nucleus; Sympatholytics; Synaptic Transmission | 2005 |
6-pyruvoyl-tetrahydropterin synthase deficiency with mild hyperphenylalaninemia.
Topics: 5-Hydroxytryptophan; Biopterins; Carbidopa; Cerebral Palsy; Child; Developmental Disabilities; Diagnostic Errors; Dopamine Agents; Female; Humans; Levodopa; Movement Disorders; Phenylalanine; Phenylketonurias; Phosphorus-Oxygen Lyases; Seizures | 2005 |
Camptocormia in a patient with multiple system atrophy.
Topics: Antiparkinson Agents; Cerebellum; Disease Progression; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Multiple System Atrophy; Nerve Tissue Proteins; Oligodendroglia; Posture; Spinal Diseases; Synucleins | 2005 |
Quantitative measurements of alternating finger tapping in Parkinson's disease correlate with UPDRS motor disability and reveal the improvement in fine motor control from medication and deep brain stimulation.
Topics: Biomechanical Phenomena; Brain; Deep Brain Stimulation; Disability Evaluation; Dopamine Agonists; Electrodes, Implanted; Electromyography; Fingers; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Periodicity; Postoperative Care; Preoperative Care; Severity of Illness Index; Surveys and Questionnaires; User-Computer Interface | 2005 |
The first evaluation of brain shift during functional neurosurgery by deformation field analysis.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesias; Electrodes, Implanted; Gait; Humans; Imaging, Three-Dimensional; Intraoperative Care; Levodopa; Magnetic Resonance Imaging; Male; Microelectrodes; Movement Disorders; Neurosurgical Procedures; Parkinson Disease; Psychoses, Substance-Induced; Radiosurgery; Subthalamic Nucleus | 2005 |
Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder.
Topics: Adolescent; Alcohol Oxidoreductases; Cerebral Palsy; Child; Child, Preschool; Circadian Rhythm; Cognition Disorders; Developmental Disabilities; Dopamine Agents; Dyskinesias; Female; Genotype; Humans; Levodopa; Male; Motor Activity; Movement Disorders | 2005 |
Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Immunohistochemistry; Levodopa; Male; Motor Activity; Movement Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
Orthostatic hypotension as an early finding in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Autonomic Nervous System; Diagnosis, Differential; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Movement Disorders; Multiple System Atrophy; Parkinson Disease; Time Factors | 2006 |
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations.
Topics: Aged; Anti-Bacterial Agents; Comorbidity; Double-Blind Method; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Placebo Effect; Treatment Outcome | 2006 |
MSA-C is the predominant clinical phenotype of MSA in Japan: analysis of 142 patients with probable MSA.
Topics: Adult; Aged; Antiparkinson Agents; Autonomic Nervous System; Cerebellar Ataxia; Death, Sudden; Diagnostic Imaging; Drug Resistance; Female; Follow-Up Studies; Humans; Japan; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Multiple System Atrophy; Parkinsonian Disorders; Phenotype; Retrospective Studies; Vocal Cord Paralysis | 2006 |
Case records of the Massachusetts General Hospital. Case 26-2006. A 19-year-old woman with difficulty walking.
Topics: Adult; Diagnosis, Differential; Dystonia; Dystonic Disorders; Female; Gait Disorders, Neurologic; GTP Cyclohydrolase; Humans; Levodopa; Movement Disorders | 2006 |
Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Electrophoresis, Gel, Two-Dimensional; Gene Expression Profiling; Levodopa; Macaca fascicularis; Movement Disorders; Nerve Tissue Proteins; Parkinson Disease, Secondary; Proteome | 2006 |
Detection of motor and non-motor symptoms of end-of dose wearing-off in Parkinson's disease using a dedicated questionnaire: a Belgian multicenter survey.
Topics: Aged; Antiparkinson Agents; Anxiety; Belgium; Humans; Levodopa; Mood Disorders; Movement Disorders; Parkinson Disease; Surveys and Questionnaires | 2006 |
The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration.
Topics: Analysis of Variance; Animals; Brain Injuries; Bromocriptine; Cell Count; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Routes; Female; Immunohistochemistry; Levodopa; Lipopolysaccharides; Movement Disorders; Oxidopamine; Rats; Rats, Sprague-Dawley; Rotarod Performance Test; Time Factors; Tyrosine 3-Monooxygenase | 2007 |
Dopa-responsive hypersomnia and mixed movement disorder due to sepiapterin reductase deficiency.
Topics: Adult; Alcohol Oxidoreductases; Disorders of Excessive Somnolence; Female; Humans; Levodopa; Metabolic Diseases; Movement Disorders | 2006 |
[Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Depression; Disability Evaluation; Dopamine Agonists; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 2007 |
Dopa-responsive camptocormia in a patient with multiple system atrophy.
Topics: 3-Iodobenzylguanidine; Antiparkinson Agents; Female; Heart; Humans; Levodopa; Middle Aged; Movement; Movement Disorders; Multiple System Atrophy; Parkinson Disease; Posture; Radionuclide Imaging; Radiopharmaceuticals | 2008 |
Functional consequences of iron overload in catecholaminergic interactions: the Youdim factor.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Brain Chemistry; Catecholamines; Clozapine; Denervation; Dopamine; Dopamine Agents; Female; Haloperidol; Iron; Iron Overload; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Movement Disorders; MPTP Poisoning; Norepinephrine; Pregnancy; Psychotic Disorders; Signal Transduction; Weight Gain | 2007 |
Quality of life scale in Parkinson's disease PDQ-39 - (Brazilian Portuguese version) to assess patients with and without levodopa motor fluctuation.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Quality of Life; Reproducibility of Results; Severity of Illness Index; Sickness Impact Profile; Surveys and Questionnaires | 2007 |
Novel pattern of levodopa-related motor fluctuations: 'paradoxical'on.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinsonian Disorders | 2008 |
Clinical heterogeneity in newly diagnosed Parkinson's disease.
Topics: Adult; Age Distribution; Age of Onset; Aged; Aged, 80 and over; Anxiety Disorders; Cluster Analysis; Cohort Studies; Comorbidity; Depressive Disorder; Disability Evaluation; Disease Progression; Female; Humans; Immunity, Innate; Levodopa; Male; Middle Aged; Movement Disorders; Netherlands; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Quality of Life | 2008 |
Managing Parkinson's disease with continuous dopaminergic stimulation.
Topics: Dopamine Agonists; Drug Administration Routes; Humans; Injections, Intravenous; Levodopa; Movement Disorders; Parkinson Disease | 2008 |
[Precoce survey: a new self-assessment patient card for early detection and management of Parkinson disease fluctuations].
Topics: Adult; Aged; Aged, 80 and over; Aging; Antiparkinson Agents; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Reproducibility of Results; Surveys and Questionnaires | 2008 |
The role of anticholinergic drugs in extra-pyramidal syndromes.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement Disorders; Parasympatholytics; Parkinson Disease | 1981 |
Basal ganglia disease.
Topics: Basal Ganglia Diseases; Dopamine; Humans; Huntington Disease; Levodopa; Models, Biological; Movement Disorders; Neurotransmitter Agents; Parasympatholytics; Parkinson Disease | 1982 |
Abnormalities in postural reflexes and voluntarily induced automatic movements in Parkinson patients.
Topics: Basal Ganglia; Humans; Levodopa; Movement Disorders; Parkinson Disease; Posture; Reflex, Abnormal | 1982 |
(-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease.
Topics: Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Treatment of dyskinetic and dystonic disorders with CF 25-397: clinical and pharmacological aspects.
Topics: Aged; Carbidopa; Dystonia; Ergolines; Female; Hepatolenticular Degeneration; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1980 |
Clonidine therapy for tardive dyskinesia and related syndromes.
Topics: Adult; Aged; Clonidine; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders | 1984 |
The natural history of Parkinson's disease.
Topics: Activities of Daily Living; Dementia; Dysarthria; Gait; Humans; Levodopa; Movement Disorders; Muscle Rigidity; Parkinson Disease; Thalamus; Time Factors; Tremor | 1984 |
Pharmacological basis of akinesia in Parkinson's disease.
Topics: Brain; Dopamine; Humans; Levodopa; Movement Disorders; Muscle Rigidity; Norepinephrine; Parkinson Disease; Receptors, Dopamine; Tremor | 1983 |
Symptoms and side effects in the course of Parkinson's disease.
Topics: Autonomic Nervous System Diseases; Dementia; Diagnosis, Differential; Dopamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Movement Disorders; Muscle Rigidity; Parkinson Disease; Psychoses, Substance-Induced; Receptors, Dopamine | 1983 |
Variability in Parkinson's disease; clinical aspects, causes and treatment.
Topics: Aging; Fatigue; Humans; Levodopa; Movement Disorders; Neurasthenia; Parkinson Disease; Sleep | 1983 |
Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Carbidopa; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Parkinson Disease, Secondary; Pyridines | 1984 |
The use of bromocriptine for testing central dopaminergic reactivity.
Topics: Blood Pressure; Brain; Bromocriptine; Drug Resistance; Humans; Levodopa; Movement Disorders; Parkinson Disease; Receptors, Dopamine; Renin | 1980 |
Abnormal involuntary movements: a study of dopaminergic receptor interaction.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parasympatholytics; Parasympathomimetics; Parkinson Disease; Receptors, Dopamine | 1983 |
The effect of lithium on the "on-off" phenomenon in parkinsonism.
Topics: Adult; Double-Blind Method; Female; Humans; Levodopa; Lithium; Male; Middle Aged; Movement Disorders; Parkinson Disease; Random Allocation | 1983 |
Clinical analysis of akinesia.
Topics: Dopamine; Humans; Levodopa; Motor Skills; Movement Disorders; Muscle Rigidity; Parkinson Disease; Thalamus | 1980 |
Effect of naloxone on the "on-off' syndrome in patients receiving long-term levodopa therapy.
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Naloxone; Parkinson Disease; Receptors, Dopamine | 1982 |
Pharmacology of blepharospasm-oromandibular dystonia syndrome.
Topics: Aged; Benztropine; Blepharospasm; Carbidopa; Deanol; Drug Therapy, Combination; Electromyography; Eyelid Diseases; Humans; Jaw Diseases; Levodopa; Male; Middle Aged; Movement Disorders; Syndrome | 1980 |
Is L-DOPA drug holiday useful?
Topics: Activities of Daily Living; Aged; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1980 |
Levodopa aids certain movement disorders.
Topics: Humans; Levodopa; Movement Disorders | 1981 |
[Gait disorders and repeated falls in Steele-Richardson-Olszewski syndrome].
Topics: Accidental Falls; Aged; Cognition Disorders; Female; Gait; Humans; Levodopa; Magnetic Resonance Spectroscopy; Movement Disorders; Neurotransmitter Agents; Posture; Saccades; Supranuclear Palsy, Progressive; Tomography, X-Ray Computed | 1995 |
New pathophysiology of Parkinson's disease revealed by posteroventral pallidotomy.
Topics: Combined Modality Therapy; Gait; Globus Pallidus; Humans; Levodopa; Movement Disorders; Parkinson Disease; Serotonin; Thalamus; Treatment Outcome; Tremor | 1995 |
Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Apomorphine; Brain Tissue Transplantation; Carbidopa; Dextroamphetamine; Disease Models, Animal; Dopamine; Dopamine Agonists; Ergolines; Female; Fetal Tissue Transplantation; Forelimb; Functional Laterality; Levodopa; Motor Activity; Movement Disorders; Norepinephrine; Oxidopamine; Parkinson Disease; Quinpirole; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Transplantation, Heterotopic | 1995 |
Remission in dihydroxyphenylalanine-responsive dystonia.
Topics: Child; Dihydroxyphenylalanine; Dystonia; Humans; Levodopa; Male; Movement Disorders; Treatment Outcome | 1995 |
Which factors predict cognitive decline in Parkinson's disease?
Topics: Activities of Daily Living; Age of Onset; Aged; Cognition Disorders; Depressive Disorder; Educational Status; Humans; Levodopa; Middle Aged; Movement Disorders; Neuropsychological Tests; Parkinson Disease; Prognosis; Severity of Illness Index; Task Performance and Analysis; Tremor | 1995 |
[Aggravation of Parkinson's disease after inadequate use of levodopa in controlled-release preparations].
Topics: Aged; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1995 |
Chronic haloperidol: neural correlates of motor disorders in an invertebrate model.
Topics: Animals; Catecholamines; Disease Models, Animal; Dopamine; Fluorescence; Glyoxylates; Haloperidol; Histocytochemistry; Leeches; Levodopa; Locomotion; Movement; Movement Disorders; Neurotransmitter Agents | 1994 |
Clinical features and natural history of multiple system atrophy. An analysis of 100 cases.
Topics: Adult; Aged; Brain Diseases; Cerebellar Diseases; Corpus Striatum; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Olivopontocerebellar Atrophies; Parkinson Disease; Substantia Nigra; Tremor | 1994 |
[Catecholamines and the dopamine-beta-hydroxylase activity of the blood plasma in motor pathology in children: the role of central and peripheral mechanisms].
Topics: Adolescent; Carbidopa; Catecholamines; Child; Chromatography, High Pressure Liquid; Dopamine Agonists; Dopamine beta-Hydroxylase; Drug Combinations; Female; Humans; Levodopa; Male; Movement Disorders; Spectrophotometry | 1994 |
[Disappearance of akinesia in Parkinson disease during a manic attack].
Topics: Aged; Bipolar Disorder; Dopamine; Female; Humans; Levodopa; Motor Activity; Movement Disorders; Parkinson Disease | 1993 |
[Akinetic crisis in Parkinson disease].
Topics: Aged; Aged, 80 and over; Apomorphine; Benserazide; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1994 |
[A case of rabbit syndrome--its unique pharmacological feature].
Topics: Antipsychotic Agents; Extrapyramidal Tracts; Female; Humans; Levodopa; Lip; Middle Aged; Movement Disorders; Syndrome | 1993 |
Parkinson's disease dyskinesias.
Topics: Clozapine; Dose-Response Relationship, Drug; Humans; Levodopa; Movement Disorders; Parkinson Disease | 1994 |
Parkinson's disease dyskinesias.
Topics: Dose-Response Relationship, Drug; Humans; Levodopa; Movement Disorders; Parkinson Disease | 1994 |
[Parkinson's disease: modern evolution].
Topics: Humans; Intelligence; Levodopa; Movement Disorders; Parkinson Disease | 1993 |
Risk factors on the occurrence of response fluctuations and dyskinesias in Parkinson's disease.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Regression Analysis; Risk Factors | 1993 |
[Rhythmical involuntary movement at rest associated with olivo-ponto-cerebellar atrophy (OPCA)].
Topics: Adolescent; Aged; Brain; Clonazepam; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Olivopontocerebellar Atrophies; Parkinson Disease; Rest; Trihexyphenidyl | 1993 |
Primary progressive freezing gait.
Topics: Aged; Diagnosis, Differential; Droxidopa; Female; Gait; Humans; Levodopa; Locomotion; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Neurologic Examination; Parkinson Disease; Posture; Tomography, X-Ray Computed | 1993 |
The spectrum of levodopa-related fluctuations in Parkinson's disease.
Topics: Aged; Depression; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Restless Legs Syndrome; Urinary Incontinence | 1993 |
Progression after chronic manganese exposure.
Topics: Adult; Chronic Disease; Follow-Up Studies; Humans; Levodopa; Male; Manganese; Middle Aged; Movement Disorders; Nervous System Diseases; Occupational Exposure; Parkinson Disease, Secondary | 1993 |
Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Tyrosine | 1993 |
Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa.
Topics: Aged; Circadian Rhythm; Female; Humans; Levodopa; Male; Melatonin; Middle Aged; Movement Disorders; Muscle Rigidity; Parkinson Disease; Radioimmunoassay; Tremor | 1993 |
Early detection of L-dopa response in parkinsonian patients with a standardized tracking test.
Topics: Adult; Basal Ganglia; Benserazide; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Movement Disorders; Muscle Rigidity; Neurologic Examination; Orientation; Parkinson Disease; Psychomotor Performance; Signal Processing, Computer-Assisted; Tremor | 1993 |
Impaired activity of the supplementary motor area in akinetic patients with Parkinson's disease. Improvement by the dopamine agonist apomorphine.
Topics: Aged; Apomorphine; Brain; Dopamine; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Motor Activity; Motor Cortex; Movement Disorders; Muscle Rigidity; Neurologic Examination; Parkinson Disease; Regional Blood Flow; Somatosensory Cortex; Tomography, Emission-Computed, Single-Photon | 1993 |
Dopa-unresponsive pure akinesia or freezing. A condition within a wide spectrum of PSP?
Topics: Benserazide; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Humans; Levodopa; Motor Activity; Movement Disorders; Neurologic Examination; Ocular Motility Disorders; Parkinson Disease; Parkinson Disease, Secondary; Supranuclear Palsy, Progressive | 1993 |
Is the decreasing responsiveness of axial motor symptoms to L-dopa in elderly parkinsonian patients related to age-associated nonparkinsonian pathologies?
Topics: Age Factors; Aged; Brain; Dementia; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Motor Activity; Motor Skills; Movement Disorders; Muscle Rigidity; Neurologic Examination; Parkinson Disease | 1993 |
Clinical features and medical treatment of Parkinson's disease in patient groups selected in accordance with age at onset.
Topics: Adult; Age Factors; Aged; Dose-Response Relationship, Drug; Dystonia; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Movement Disorders; Neurologic Examination; Parkinson Disease; Risk Factors | 1993 |
A clinicopathologic study of 100 cases of Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Female; Humans; Levodopa; Lewy Bodies; Male; Middle Aged; Movement Disorders; Nervous System Diseases; Parkinson Disease; Survival Analysis | 1993 |
Rehabilitation of patients with Hallervorden-Spatz syndrome.
Topics: Activities of Daily Living; Adult; Carbidopa; Drug Therapy, Combination; Exercise Therapy; Humans; Levodopa; Male; Movement Disorders; Pantothenate Kinase-Associated Neurodegeneration; Patient Care Team | 1993 |
Sustained-release levodopa in parkinsonian patients with nocturnal disabilities.
Topics: Aged; Aged, 80 and over; Delayed-Action Preparations; Humans; Levodopa; Longitudinal Studies; Middle Aged; Movement Disorders; Parkinson Disease; Sleep Wake Disorders | 1993 |
Response to L-DOPA in multiple system atrophy.
Topics: Adult; Aged; Carbidopa; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement; Movement Disorders; Muscle Rigidity; Olivopontocerebellar Atrophies; Parkinson Disease; Tremor | 1993 |
Benign paroxysmal tonic upgaze of childhood with ataxia. A neuro-ophthalmological syndrome of familial origin?
Topics: Age Factors; Ataxia; Carbidopa; Eye Movements; Family; Humans; Infant; Levodopa; Male; Movement Disorders; Ocular Motility Disorders; Posture; Sleep; Syndrome | 1993 |
S-adenosyl-L-methionine decreases motor activity in the rat: similarity to Parkinson's disease-like symptoms.
Topics: Animals; Behavior, Animal; Catecholamines; Immobilization; Levodopa; Male; Movement Disorders; Parkinson Disease; Rats; Rats, Sprague-Dawley; S-Adenosylmethionine; Tremor | 1993 |
Effects of levodopa and viscosity on the velocity and accuracy of visually guided tracking in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Data Interpretation, Statistical; Female; Humans; Levodopa; Male; Middle Aged; Movement; Movement Disorders; Neural Conduction; Parkinson Disease; Photic Stimulation; Psychomotor Performance; Viscosity | 1996 |
Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients.
Topics: Analysis of Variance; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Treatment Outcome | 1995 |
[Parkinsonian syndrome and post-encephalitic stereotyped involuntary movements responsive to L-dopa].
Topics: Adult; Dopamine Agents; Encephalitis; Encephalitis, Viral; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease, Postencephalitic; Time Factors | 1996 |
Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients.
Topics: Adult; Aged; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Retrospective Studies; Risk Factors; Time Factors | 1996 |
Acute pharmacologic blockade of dyskinesias in Parkinson's disease.
Topics: Dextrorphan; Double-Blind Method; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Placebos; Severity of Illness Index | 1996 |
[Keratitis and corneal edema associated with levodopa use--a case report].
Topics: Adult; Antiparkinson Agents; Apraxias; Corneal Edema; Female; Humans; Hypoxia, Brain; Keratitis; Levodopa; Movement Disorders | 1996 |
Levodopa therapy improves motor function in HIV-infected children with extrapyramidal syndromes.
Topics: Child, Preschool; Female; HIV Infections; Humans; Levodopa; Male; Movement Disorders; Syndrome | 1996 |
Disordered axial movement in Parkinson's disease.
Topics: Adult; Aged; Female; Gait; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1996 |
Ventrolateral thalamotomy for dyskinesia following levodopa therapy of Parkinson's disease.
Topics: Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Stereotaxic Techniques; Thalamic Nuclei; Tomography, X-Ray Computed | 1996 |
Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Myoclonus; Parkinson Disease; Prospective Studies; Retrospective Studies; Tremor | 1997 |
Usefulness of pallidotomy in advanced Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Female; Follow-Up Studies; Globus Pallidus; Humans; Intraoperative Complications; Levodopa; Lifting; Male; Middle Aged; Movement; Movement Disorders; Parkinson Disease; Pilot Projects; Prospective Studies; Reoperation; Statistics, Nonparametric; Tomography, X-Ray Computed; Treatment Outcome; Tremor; Video Recording | 1997 |
Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study.
Topics: Fixation, Ocular; Gait; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Supranuclear Palsy, Progressive | 1997 |
Atypical parkinsonism in a family of Portuguese ancestry: absence of CAG repeat expansion in the MJD1 gene.
Topics: Adult; Base Sequence; Eye Diseases; Female; Genes; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Mutation; Parkinson Disease; Pedigree; Portugal; Repetitive Sequences, Nucleic Acid; Spinocerebellar Degenerations | 1997 |
Clinical and pharmacological differences in early- versus late-onset Parkinson's disease.
Topics: Adult; Age Factors; Age of Onset; Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Retrospective Studies; Severity of Illness Index | 1997 |
Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
Topics: Adult; Aged; Amino Acids; Antiparkinson Agents; Brain; Carbidopa; Circadian Rhythm; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Severity of Illness Index; Time Factors | 1997 |
Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carbidopa; Cell Transplantation; Disease Models, Animal; Dopamine; Drug Combinations; Drug Synergism; Levodopa; Male; Movement Disorders; Neostriatum; Parkinson Disease, Secondary; PC12 Cells; Rats; Rats, Sprague-Dawley; Rotation | 1997 |
In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias.
Topics: Adult; Aged; Carbon Radioisotopes; Corpus Striatum; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Raclopride; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides | 1997 |
High-frequency stimulation of the globus pallidus internalis in Parkinson's disease: a study of seven cases.
Topics: Adult; Disease Progression; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Follow-Up Studies; Gait; Globus Pallidus; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Parkinson Disease; Speech Disorders; Stereotaxic Techniques; Thalamic Nuclei; Treatment Outcome; Tremor | 1997 |
[Parkinson disease--a movement disorder].
Topics: Dopamine Agonists; Humans; Levodopa; Movement Disorders; Parkinson Disease | 1997 |
[A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
Topics: Aged; Bromocriptine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Parkinson Disease; Pergolide; Retrospective Studies; Tremor | 1997 |
Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Carbidopa; Catechols; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Levodopa; Male; Movement Disorders; Nitriles; Severity of Illness Index | 1997 |
Pharmacologic management of movement disorder after midbrain haemorrhage.
Topics: Activities of Daily Living; Adult; Brain Neoplasms; Carbidopa; Cavernous Sinus; Central Nervous System Stimulants; Cerebral Hemorrhage; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Hemangioma, Cavernous; Humans; Levodopa; Male; Mesencephalon; Methamphetamine; Movement Disorders; Substance-Related Disorders | 1998 |
Gamma knife radiosurgery as a lesioning technique in movement disorder surgery.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Dopamine Agents; Dyskinesia, Drug-Induced; Electroencephalography; Female; Follow-Up Studies; Gait; Globus Pallidus; Hemianopsia; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Skills; Movement Disorders; Muscle Rigidity; Neuropsychological Tests; Parkinson Disease; Radiosurgery; Radiotherapy Dosage; Safety; Single-Blind Method; Thalamus; Tremor | 1998 |
[Dementia--Parkinson disease: role of antiglutamatergic drugs. Symposium: 4 April, Hamburg].
Topics: Amantadine; Antipsychotic Agents; Dementia; Humans; Levodopa; Movement Disorders; Parkinson Disease; Selective Serotonin Reuptake Inhibitors | 1998 |
Pallidotomy revisited. Analysis of posteroventral pallidotomy.
Topics: Aged; Dyskinesia, Drug-Induced; Globus Pallidus; Humans; Levodopa; MMPI; Movement Disorders; Muscle Rigidity; Parkinson Disease; Postoperative Period; Stereotaxic Techniques; Thalamic Nuclei; Thalamus; Treatment Outcome; Tremor | 1997 |
Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1998 |
Disordered locomotion in the AS/AGU mutant rat and the effects of L-dopa or fetal midbrain grafts.
Topics: Age Factors; Animals; Antiparkinson Agents; Brain Tissue Transplantation; Corpus Striatum; Fetal Tissue Transplantation; Levodopa; Locomotion; Mesencephalon; Movement Disorders; Rats; Rats, Mutant Strains | 1998 |
Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Topics: Amantadine; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Dextromethorphan; Dextrorphan; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Levodopa; Movement Disorders; Parkinson Disease; Psychomotor Performance; Receptors, N-Methyl-D-Aspartate | 1998 |
Slowly progressive L-DOPA nonresponsive pure akinesia due to nigropallidal degeneration: a clinicopathological case study.
Topics: Disease Progression; Dopamine Agents; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Neurodegenerative Diseases; Substantia Nigra; Treatment Failure | 1998 |
D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Female; Levodopa; Locomotion; Macaca fascicularis; Movement Disorders; Parkinson Disease, Secondary; Receptors, Dopamine D1 | 1999 |
[Combination therapy with lisuride and L-dopa in the early stages of Parkinson's disease decreases and delays the development of motor fluctuations. Long-term study over 10 years in comparison with L-dopa monotherapy].
Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Middle Aged; Movement Disorders; Prospective Studies; Random Allocation; Time Factors | 1999 |
Subthalamic nucleus stimulation improves directly levodopa induced dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Electric Stimulation Therapy; Electrodes, Implanted; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Thalamic Nuclei; Thalamus | 1999 |
Movement disorders in encephalitis induced by Rhodococcus aurantiacus infection relieved by the administration of L-dopa and anti-T-cell antibodies.
Topics: Actinomycetales Infections; Animals; Antiparkinson Agents; Autoantibodies; Brain; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Colony Count, Microbial; Combined Modality Therapy; Encephalitis; Female; Flow Cytometry; Levodopa; Mice; Movement Disorders; Rhodococcus; Statistics, Nonparametric | 1999 |
Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations.
Topics: Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Movement Disorders; Parkinson Disease; Presynaptic Terminals; Substantia Nigra; Tomography, Emission-Computed | 2000 |
Movement disorders secondary to adulterated medication.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Drug Contamination; Female; Humans; Levodopa; Male; Metoclopramide; Middle Aged; Movement Disorders; Peru; Product Surveillance, Postmarketing | 2000 |
Pharmacological analysis of extracellular dopamine and metabolites in the striatum of conscious as/agu rats, mutants with locomotor disorder.
Topics: Amphetamine; Animals; Clorgyline; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Uptake Inhibitors; Extracellular Space; Levodopa; Male; Mice; Mice, Mutant Strains; Monoamine Oxidase Inhibitors; Movement Disorders; Nomifensine; Potassium; Reference Values | 2000 |
Clinical problems in non-fluctuating patients with Parkinson's disease: a community-based study.
Topics: Age of Onset; Aged; Antiparkinson Agents; Case-Control Studies; Dementia; Depression; Diabetes Mellitus; Drug Tolerance; Fatigue; Female; Humans; Levodopa; Male; Movement Disorders; Neurologic Examination; Norway; Outpatients; Parkinson Disease; Prevalence; Psychomotor Performance; Quality of Life; Severity of Illness Index; Sleep Wake Disorders; Surveys and Questionnaires | 2000 |
L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations.
Topics: Animals; Behavior, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Movement Disorders | 2001 |
Acceleration of HIV dementia with methamphetamine and cocaine.
Topics: Adult; AIDS Dementia Complex; Amphetamine-Related Disorders; Antiretroviral Therapy, Highly Active; Blood-Brain Barrier; Brain; Cholinergic Antagonists; Cocaine-Related Disorders; Disease Progression; Humans; Levodopa; Magnetic Resonance Imaging; Male; Methamphetamine; Movement Disorders | 2001 |
Post-stroke violent adventitial movement responsive to levo-dopa/carbi-dopa therapy.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Basal Ganglia; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Movement Disorders; Stroke; Treatment Outcome; Tremor | 2001 |
Influence of pallidal stimulation and levodopa on gait and preparatory postural adjustments in Parkinson's disease.
Topics: Antiparkinson Agents; Combined Modality Therapy; Disability Evaluation; Electric Stimulation Therapy; Female; Gait; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Posture | 2002 |
The clinical profile of nonmotor fluctuations in Parkinson's disease patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Dopamine Agents; Humans; Levodopa; Mental Disorders; Middle Aged; Movement Disorders; Parkinson Disease; Sensation Disorders; Surveys and Questionnaires; Time Factors | 2002 |
Letter: Diphasic dyskinesia during levodopa therapy.
Topics: Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1975 |
Letter: Dyskinesias during levodopa therapy.
Topics: Humans; Levodopa; Movement Disorders; Parkinson Disease; Time Factors | 1975 |
[Long-term treatment with L-DOPA in a case of torsion dystonia (authors transl)].
Topics: Adult; Basal Ganglia; Dystonia Musculorum Deformans; Female; Humans; Levodopa; Movement Disorders | 1975 |
"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.
Topics: Dose-Response Relationship, Drug; Half-Life; Levodopa; Long-Term Care; Movement Disorders; Muscle Rigidity; Parkinson Disease; Time Factors | 1976 |
"Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease.
Topics: Athetosis; Chorea; Dystonia Musculorum Deformans; Female; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease | 1977 |
Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl.
Topics: Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1979 |
Diphenylhydantoin. Blocking of levodopa effects.
Topics: Adult; Aged; Dopamine; Female; Humans; Huntington Disease; Levodopa; Male; Manganese Poisoning; Middle Aged; Movement Disorders; Neurons; Parkinson Disease; Phenytoin; Receptors, Adrenergic | 1975 |
Therapeutics of disordered movement.
Topics: Carbidopa; Chorea; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dystonia Musculorum Deformans; Hepatolenticular Degeneration; Humans; Huntington Disease; Levodopa; Movement Disorders; Parasympatholytics; Parkinson Disease; Receptors, Cholinergic; Receptors, Dopamine; Tremor | 1977 |
Modification of involuntary movements by centrally acting drugs.
Topics: Aminooxyacetic Acid; Animals; Atropine; Bicuculline; Bromocriptine; Dopamine; Haloperidol; Haplorhini; Levodopa; Movement Disorders; Physostigmine; Picrotoxin; Piperazines; Piribedil; Receptors, Drug; Synaptic Transmission; Thalamic Nuclei; Theophylline | 1975 |
Schizophrenia: a theory.
Topics: Cognition; Dopamine; Dopamine beta-Hydroxylase; Dreams; Feedback; Fusaric Acid; Humans; Levodopa; Models, Psychological; Movement Disorders; Norepinephrine; Schizophrenia; Schizophrenic Psychology; Sleep, REM; Stress, Psychological | 1976 |
[New trends in clinical neurology].
Topics: Brain; Brain Diseases; Cerebral Cortex; Epilepsy; Evoked Potentials; Humans; Levodopa; Motor Neurons; Movement Disorders; Nervous System Diseases; Neurons; Pain; Radiculopathy; Spinal Nerves; Synaptic Transmission | 1976 |
[Therapeutic use of tiapride in movement disorders].
Topics: Benzamides; Chorea; Chronic Disease; Drug Tolerance; Female; Humans; Huntington Disease; Levodopa; Movement Disorders; Parkinson Disease | 1978 |
The treatment of the choreas and athetotic dystonias.
Topics: Adult; Athetosis; Benzodiazepines; Child; Chorea; Dystonia; Haloperidol; Humans; Levodopa; Movement Disorders; Phenelzine; Phenothiazines; Pimozide; Tetrabenazine; Valproic Acid | 1979 |
Relationship between tardive dyskinesia, L-Dopa-induced hyperkinesia and parkinsonism.
Topics: Adult; Age Factors; Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Oral Manifestations; Parkinson Disease; Tranquilizing Agents | 1977 |
Acute dystonia as an idiosyncratic response to neuroleptics in baboons.
Topics: 5-Hydroxytryptophan; Acute Disease; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Haloperidol; Haplorhini; Humans; Levodopa; Movement Disorders; Papio; Parasympatholytics; Physostigmine; Pimozide; Receptors, Dopamine; Reserpine; Syndrome; Tranquilizing Agents | 1977 |
[Therapy of rigidity and hypokinesis in old age using Sinemet].
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Movement Disorders; Muscle Rigidity; Parkinson Disease, Postencephalitic; Trihexyphenidyl | 1979 |
Paroxysmal dyskinesia.
Topics: Electroencephalography; Epilepsy; Humans; Levodopa; Movement Disorders | 1979 |
[Abnormal movements induced by psychotropic drugs].
Topics: Chorea; Dyskinesia, Drug-Induced; Humans; Levodopa; Lithium; Movement Disorders; Parkinson Disease, Secondary; Psychotropic Drugs; Receptors, Dopamine; Receptors, Drug; Tremor | 1979 |
Administration of human somatotropin in levodopa-treated patients with Parkinsonism.
Topics: Aged; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1979 |
Movement disorders of aged rats: reversal by dopamine receptor stimulation.
Topics: Aging; Animals; Apomorphine; Levodopa; Male; Movement Disorders; Rats; Receptors, Dopamine; Swimming; Time Factors | 1979 |
Role of the caudate nucleus in production of dyskinesia [proceedings].
Topics: Animals; Apomorphine; Cats; Caudate Nucleus; Dopamine; Dyskinesia, Drug-Induced; Electric Stimulation; Levodopa; Movement Disorders; Neural Pathways; Substantia Nigra; Tremor | 1979 |
Ventricular fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in patients with movement disorders.
Topics: Adult; Aged; Cerebral Palsy; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Middle Aged; Movement Disorders; Multiple Sclerosis; Parkinson Disease; Phenylacetates | 1978 |
The role of bromocriptine in the treatment of parkinsonism.
Topics: Aged; Bromocriptine; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1979 |
CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders.
Topics: Aged; Athetosis; Carbidopa; Chorea; Dihydroxyphenylalanine; Dopamine; Dystonia Musculorum Deformans; Hepatolenticular Degeneration; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methoxyhydroxyphenylglycol; Middle Aged; Movement Disorders; Parkinson Disease; Parkinson Disease, Postencephalitic; Serotonin; Tetrabenazine; Torticollis | 1977 |
Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea.
Topics: Adult; Basal Ganglia Diseases; Central Nervous System; Dyskinesia, Drug-Induced; Dyspnea; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Receptors, Dopamine; Tranquilizing Agents | 1978 |
Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias.
Topics: Aged; Benzimidazoles; Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1978 |
The L-dopa on-off effect in Parkinson disease: treatment by transient drug withdrawal and dopamine receptor resensitization.
Topics: Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Receptors, Dopamine | 1978 |
L-deprenyl treatment of on-off phenomena in Parkinson's disease.
Topics: Aged; Benserazide; Dopamine; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline; Vanilmandelic Acid | 1978 |
Dystonic movement disorders and their treatment--report of three cases.
Topics: Adolescent; Adult; Child; Dystonia Musculorum Deformans; Electromyography; Humans; Levodopa; Male; Movement Disorders; Remission, Spontaneous | 1978 |
Electrical properties of motor units in Parkinsonism and a possible relationship with bradykinesia.
Topics: Action Potentials; Adult; Aged; Carbidopa; Electromyography; Forearm; Gait; Hand; Humans; Levodopa; Male; Middle Aged; Motor Skills; Movement Disorders; Muscle Contraction; Muscles; Neuromuscular Junction; Parkinson Disease; Recruitment, Neurophysiological | 1979 |
[Permanence of indications of stereotaxic surgery in parkinsonian tremors and various persistent abnormal movements].
Topics: Humans; Levodopa; Methods; Movement Disorders; Parkinson Disease; Stereotaxic Techniques | 1975 |
Stereotaxic lesions and movement disorders in monkeys.
Topics: Animals; Brain; Brain Mapping; Butyrophenones; Catalepsy; Catatonia; Cerebellum; Chorea; Haplorhini; Humans; Hypothalamus, Posterior; Levodopa; Mesencephalon; Methyltyrosines; Monoamine Oxidase Inhibitors; Motor Cortex; Movement Disorders; Parasympatholytics; Phenothiazines; Pons; Reserpine; Stereotaxic Techniques; Substantia Nigra; Tremor | 1975 |
Structural and systems approach to central representation of motor functions: importance of state dependent reactions.
Topics: Animals; Brain Mapping; Central Nervous System; Conditioning, Classical; Dopamine; Haplorhini; Humans; Levodopa; Motor Cortex; Motor Skills; Movement Disorders | 1975 |
On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients.
Topics: Administration, Oral; Aged; Blood Pressure; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Female; Humans; Hyperkinesis; Infusions, Parenteral; Levodopa; Long-Term Care; Male; Middle Aged; Movement Disorders; Parkinson Disease; Posture; Time Factors | 1975 |
Deanol in L-dopa and tardive dyskinesias: a review.
Topics: Deanol; Ethanolamines; Humans; Levodopa; Movement Disorders; Phenothiazines | 1975 |
Six years of high-level levodopa therapy in severely akinetic parkinsonian patients.
Topics: Activities of Daily Living; Drug Evaluation; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Movement Disorders; Parkinson Disease; Patient Dropouts; Prognosis | 1976 |
Role of manganese in dystonia.
Topics: Animals; Brain; Brain Chemistry; Dogs; Dystonia Musculorum Deformans; Functional Laterality; Gait; Haplorhini; Humans; Levodopa; Manganese; Manganese Poisoning; Movement Disorders; Parkinson Disease; Rabbits; Rats; Synapses; Syndrome | 1976 |
The role of the basal ganglia in the initiation of movement.
Topics: Age Factors; Animals; Basal Ganglia; Caudate Nucleus; Eye Movements; Globus Pallidus; Haplorhini; Levodopa; Macaca mulatta; Motor Activity; Movement Disorders; Putamen | 1976 |
[Treatment of Parkinson's disease with the combination drug L-carbidopa/L-dopa. Report on a 2 years study].
Topics: Carbidopa; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Movement Disorders; Parkinson Disease; Psychoses, Substance-Induced | 1977 |
Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa.
Topics: Amantadine; Chorea; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methylhistamines; Middle Aged; Movement Disorders; Parkinson Disease; Phenylacetates; Tremor | 1977 |
Problems in the treatment of Parkinsonism.
Topics: Antiparkinson Agents; Arteriosclerosis; Carbidopa; Diagnosis, Differential; Drug Combinations; Eye Manifestations; Humans; Levodopa; Mental Disorders; Movement Disorders; Parasympatholytics; Paresthesia; Parkinson Disease; Vision Disorders | 1977 |
[Dopamine beta hydroxylase. Value and limits of its study in neurology].
Topics: Amantadine; Cold Temperature; Dopamine beta-Hydroxylase; Epilepsy; Humans; Levodopa; Movement Disorders; Parkinson Disease, Secondary; Quadriplegia | 1976 |
Six-year results of treatment with levodopa plus benzerazide in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Patient Dropouts; Time Factors | 1976 |
Primary sensory symptoms in parkinsonism.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Pain; Paresthesia; Parkinson Disease; Parkinson Disease, Postencephalitic; Restless Legs Syndrome; Sensation | 1976 |
Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
Topics: Aged; Amantadine; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Movement Disorders; Parasympatholytics; Parkinson Disease; Piperazines; Piribedil | 1976 |
[Review of problems in the treatment of the parkinsonian syndrome with L-dopa].
Topics: Arrhythmias, Cardiac; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Hypertension; Hypotension, Orthostatic; Levodopa; Movement Disorders; Parkinson Disease, Secondary; Psychoses, Substance-Induced | 1976 |
[Oral dyskinesia (author's transl)].
Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Masticatory Muscles; Movement Disorders; Tongue Habits; Trihexyphenidyl | 1976 |
Levodopa-induced myoclonus.
Topics: 5-Hydroxytryptophan; Aged; Amantadine; Amphetamine; Animals; Benztropine; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Guinea Pigs; Humans; Levodopa; Male; Methysergide; Middle Aged; Movement Disorders; Myoclonus; Parkinson Disease; Propranolol; Serotonin; Serotonin Antagonists; Sleep; Trihexyphenidyl | 1975 |
Role of the strio-pallidal system and motor cortex in induced circus movements in rats and cats.
Topics: Animals; Apomorphine; Brain Mapping; Cats; Chlorpromazine; Corpus Striatum; Dextroamphetamine; Drug Interactions; Female; Haloperidol; Levodopa; Locomotion; Male; Mesencephalon; Motor Cortex; Movement Disorders; Neural Pathways; Rats | 1975 |
[Abnormal movements induced by L-dopa. New therapeutic possibilities].
Topics: Heartburn; Humans; Indenes; Levodopa; Movement Disorders; Nausea; Parkinson Disease; Pyridines; Time Factors | 1975 |
Editorial: Involuntary facial movements.
Topics: Facial Muscles; Facial Paralysis; Humans; Levodopa; Movement Disorders; Myoclonus | 1975 |
[Letter: A severe case of postural hypotension. Paradoxical treatment by L-dopa combined with an inhibitor of extracerebral dopa-decarboxylase].
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Drug Synergism; Drug Therapy, Combination; Humans; Hypotension, Orthostatic; Levodopa; Male; Movement Disorders | 1975 |
Amphetamine-induced dopaminergic hypersensitivity in guinea pigs. Implications in psychosis and human movement disorders.
Topics: Amphetamine; Animals; Apomorphine; Behavior; Behavior, Animal; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Guinea Pigs; Humans; Levodopa; Movement Disorders; Psychoses, Substance-Induced; Reaction Time; Receptors, Drug; Schizophrenia; Stereotyped Behavior; Substance-Related Disorders | 1975 |
Proceedings: The mechanism of the effect of dopamine-beta-hydroxylase inhibitor FLA-63 on the L-DOPA reversal of reserpine akinesia.
Topics: Animals; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Dopamine beta-Hydroxylase; Imidazoles; Levodopa; Mice; Motor Activity; Movement Disorders; Reserpine; Time Factors | 1975 |
Abnormal involuntary movements in relation to anticholinergics and levodopa therapy.
Topics: Benserazide; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Movement Disorders; Parasympatholytics; Parkinson Disease | 1975 |
L-dopa therapy combined with peripheral decarboxylase inhibitor (MK-486) in Parkinsonism.
Topics: Adult; Aged; Animals; Carbidopa; Carboxy-Lyases; Cats; Dopamine; Drug Therapy, Combination; Female; Humans; Hydrazines; Injections, Intraperitoneal; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1975 |
Sequential analysis: manganese, catecholamines and L-dopa induced dyskinesia.
Topics: Animals; Brain Chemistry; Cats; Caudate Nucleus; Cerebral Cortex; Corpus Callosum; Dihydroxyphenylalanine; Dopamine; Hypothalamus; Levodopa; Male; Manganese; Methods; Movement Disorders | 1975 |
Deanol in the treatment of levodopa-induced dyskinesias.
Topics: Aged; Deanol; Drug Evaluation; Ethanolamines; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1975 |
Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of l-dopa-induced dyskinesias.
Topics: Amphetamine; Animals; Apomorphine; Behavior; Corpus Striatum; Dextroamphetamine; Guinea Pigs; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Receptors, Drug; Stereotyped Behavior; Time Factors | 1975 |
Actions of dopaminergic agonists on motor function.
Topics: Amantadine; Animals; Apomorphine; Behavior; Dextroamphetamine; Disease Models, Animal; Dopamine Antagonists; Humans; Hyperkinesis; Levodopa; Methylphenidate; Motor Activity; Movement Disorders; Phenethylamines; Piribedil; Rats; Stereotyped Behavior; Tyrosine | 1975 |
Supersensitivity to d-amphetamine- and apomorphine-induced stereotyped behavior induced by chronic d-amphetamine administration.
Topics: Animals; Apomorphine; Behavior; Corpus Striatum; Dextroamphetamine; Disease Models, Animal; Dopamine; Humans; Levodopa; Male; Mice; Movement Disorders; Parkinson Disease; Receptors, Drug; Stereotyped Behavior; Time Factors | 1975 |
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.
Topics: Administration, Oral; Age Factors; Aged; Brain; Brain Chemistry; Circadian Rhythm; Dopamine; Drug Synergism; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Injections, Intravenous; Levodopa; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Phenethylamines | 1975 |
[The deterioration of patients with parkinsonism treated with L-dopa].
Topics: Aged; Cognition Disorders; Follow-Up Studies; Humans; Levodopa; Middle Aged; Movement Disorders; Muscle Tonus; Parkinson Disease; Postural Balance; Recurrence; Tremor | 1975 |
Diseases of the central nervous system. Involuntary movements.
Topics: Athetosis; Central Nervous System Diseases; Chorea; Face; Humans; Levodopa; Movement Disorders; Myoclonus; Parkinson Disease; Spasm; Tic Disorders; Torticollis; Tremor | 1975 |
[Animal stereotypy and transmethylation of cerebral amines].
Topics: Amines; Amphetamine; Animals; Apomorphine; Brain; Levodopa; Movement Disorders; Piribedil; Rats; S-Adenosylmethionine | 1975 |
Neuroleptics and the corpus striatum: clinical implications.
Topics: Acetylcholine; Basal Ganglia Diseases; Benztropine; Corpus Striatum; Dopamine; Fluphenazine; Haloperidol; Humans; Levodopa; Models, Neurological; Movement Disorders; Parkinson Disease; Reserpine; Schizophrenia; Tranquilizing Agents; Trihexyphenidyl | 1976 |
[Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
Topics: Administration, Sublingual; Adult; Aged; Apomorphine; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease | 1992 |
Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease.
Topics: Administration, Oral; Aged; Constipation; Dietary Fiber; Female; Gastrointestinal Motility; Humans; Intestinal Absorption; Levodopa; Male; Motor Activity; Movement Disorders; Parkinson Disease; Psychomotor Performance; Time Factors | 1992 |
Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.
Topics: Adult; Apomorphine; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1992 |
Hemiballism and chorea in a patient with parkinsonism due to a multisystem degeneration.
Topics: Aged; Antiparkinson Agents; Atrophy; Brain; Carbidopa; Central Nervous System Diseases; Chorea; Diagnosis, Differential; Drug Combinations; Female; Humans; Levodopa; Movement Disorders; Nerve Degeneration; Parkinson Disease; Spinal Cord | 1992 |
Site-specific growth of Nocardia asteroides in the murine brain.
Topics: Animals; Brain; Female; Levodopa; Mice; Mice, Inbred BALB C; Movement Disorders; Mutation; Nocardia asteroides; Substantia Nigra | 1992 |
L-dopa-responsive movement disorder caused by Nocardia asteroides localized in the brains of mice.
Topics: Animals; Brain; Disease Models, Animal; Female; Inclusion Bodies; Levodopa; Mice; Mice, Inbred BALB C; Movement Disorders; Nocardia asteroides; Nocardia Infections; Parkinson Disease; Tyrosine 3-Monooxygenase | 1991 |
Motor blocks in Parkinson's disease.
Topics: Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Risk Factors | 1992 |
Nighttime levodopa infusions to treat motor fluctuations in advanced Parkinson's disease: preliminary observations.
Topics: Drug Administration Schedule; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1991 |
Paroxysmal tremor and orofacial dyskinesia secondary to a biopterin synthesis defect.
Topics: Administration, Oral; Biopterins; Extremities; Humans; Infant; Levodopa; Male; Mouth; Movement Disorders; Phenylalanine; Tremor | 1991 |
A rare case with diurnal fluctuation of head instability, hypotonia and choreoathetotic movements improved by L-dopa treatment.
Topics: Child; Circadian Rhythm; Female; Head; Humans; Levodopa; Movement; Movement Disorders; Muscle Tonus | 1991 |
A case of pure akinesia due to Lewy body parkinson's disease with pathology.
Topics: Humans; Levodopa; Movement Disorders; Parkinson Disease | 1990 |
Response to a standard oral levodopa test in parkinsonian patients with and without motor fluctuations.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Psychomotor Performance; Reaction Time | 1990 |
Adrenal medullary transplantation into the brain for treatment of Parkinson's disease: clinical outcome and neurochemical studies.
Topics: Activities of Daily Living; Adrenal Medulla; Adult; Caudate Nucleus; Cells, Cultured; Dopamine; Epinephrine; Follow-Up Studies; Homovanillic Acid; Humans; Hydrocortisone; Levodopa; Male; Middle Aged; Movement Disorders; Nerve Growth Factors; Norepinephrine; Parkinson Disease | 1990 |
Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Apomorphine; Drug Tolerance; Ergolines; Humans; Infusion Pumps; Levodopa; Lisuride; Middle Aged; Movement Disorders; Parkinson Disease | 1990 |
Induction of dyskinesias.
Topics: Animals; Apomorphine; Delayed-Action Preparations; Levodopa; Movement Disorders; Parkinson Disease; Rats; Receptors, Dopamine | 1990 |
Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters.
Topics: Carbidopa; Catecholamines; Child; Child, Preschool; Fluphenazine; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Lesch-Nyhan Syndrome; Levodopa; Male; Methoxyhydroxyphenylglycol; Movement Disorders; Self Mutilation; Tetrabenazine | 1988 |
Clinical and pharmacokinetic evaluation of controlled-release levodopa/carbidopa (CR-4) in parkinsonian patients with severe motor fluctuations: a six month follow-up study.
Topics: Adult; Aged; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1989 |
Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Psychomotor Performance | 1989 |
Long-term clinical efficacy of Sinemet CR in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease | 1989 |
Correlates of memory in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Memory; Memory Disorders; Middle Aged; Movement Disorders; Neuropsychological Tests; Parkinson Disease | 1989 |
The prevalence and aetiology of long-term L-dopa side-effects in elderly parkinsonian patients.
Topics: Age Factors; Aged; Aged, 80 and over; Female; Hallucinations; Humans; Hypotension, Orthostatic; Levodopa; Male; Movement Disorders; Parkinson Disease; Scotland; Time Factors | 1989 |
[Development of Parkinson's disease].
Topics: Humans; Levodopa; Life Expectancy; Mental Disorders; Movement Disorders; Parkinson Disease; Prognosis | 1989 |
[Motor fluctuations in Parkinson's disease: the "New frontier" of therapeutic success. A Roche Laboratory seminar].
Topics: Antiparkinson Agents; Benserazide; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Movement Disorders; Parkinson Disease | 1989 |
Effects of etybenzatropine and diazepam on levodopa-induced diphasic dyskinesias in Parkinson's disease.
Topics: Diazepam; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Pilot Projects; Tropanes | 1989 |
Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Dose-Response Relationship, Drug; Ergolines; Injections, Intravenous; Levodopa; Macaca fascicularis; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Quinpirole; Stereotyped Behavior | 1989 |
The effects of oral protein on the absorption of intraduodenal levodopa and motor performance.
Topics: Aged; Dietary Proteins; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease, Secondary | 1989 |
[Diagnosis and treatment of Shy-Drager syndrome].
Topics: Autonomic Nervous System Diseases; Diagnosis, Differential; Drug Therapy, Combination; Ephedrine; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Mineralocorticoids; Movement Disorders; Shy-Drager Syndrome | 1989 |
L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Female; Hydroxydopamines; Levodopa; Male; Mice; Movement Disorders; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Reserpine; Stereotyped Behavior | 1987 |
Experimental study on resting tremor and L-dopa-induced dyskinesia.
Topics: Animals; Cercopithecus; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Macaca; Movement Disorders; Receptors, Dopamine; Receptors, Dopamine D2; Tegmentum Mesencephali; Tremor | 1987 |
Treatment of Parkinson's disease with subcutaneous lisuride infusions.
Topics: Aged; Drug Eruptions; Drug Therapy, Combination; Ergolines; Female; Hematoma; Humans; Infusion Pumps; Levodopa; Lisuride; Male; Mental Disorders; Middle Aged; Movement Disorders; Parkinson Disease | 1988 |
Problems in the contemporary treatment of parkinsonism.
Topics: Basal Ganglia; Dementia; Humans; Kinetics; Levodopa; Movement Disorders; Neuromuscular Junction; Parkinson Disease; Receptors, Dopamine; Synaptic Transmission | 1985 |
Restless legs syndrome and periodic movements in sleep: physiopathology and treatment with L-dopa.
Topics: Adult; Central Nervous System; Dopamine; Female; Humans; Levodopa; Male; Movement Disorders; Restless Legs Syndrome; Sleep Wake Disorders; Sodium Oxybate; Synaptic Transmission | 1986 |
Resolution of dyskinesia and the "on-off" phenomenon in thyrotoxic patients with Parkinson's disease after antithyroid treatment.
Topics: Aged; Carbimazole; Dyskinesia, Drug-Induced; Female; Humans; Hyperthyroidism; Levodopa; Movement Disorders; Parkinson Disease | 1986 |
The role of MAO-b inhibitors in the treatment of Parkinson's disease.
Topics: Adult; Aged; Depression; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1986 |
(-)Deprenyl in the treatment of decompensated Parkinson's disease.
Topics: Benserazide; Drug Combinations; Humans; Hydrazines; Levodopa; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1986 |
[A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Carbidopa; Disease Models, Animal; Drug Combinations; Electromyography; Levodopa; Macaca mulatta; Movement Disorders; Parkinson Disease, Secondary; Pyridines | 1985 |
Madopar HBS in Parkinson patients with nocturnal akinesia.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1988 |
Neuropharmacological intervention with motor system aging.
Topics: Adult; Aged; Aging; Cognition; Gait; Humans; Levodopa; Middle Aged; Movement Disorders; Neuropharmacology; Neuropsychological Tests; Parkinson Disease; Posture; Reaction Time; Sympathomimetics | 1988 |
Madopar HBS in the long-term treatment of parkinsonian patients with fluctuations in disability.
Topics: Aged; Benserazide; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1987 |
A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease.
Topics: Benserazide; Circadian Rhythm; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations.
Topics: Aged; Aged, 80 and over; Benserazide; Biological Availability; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Therapeutic value of Madopar HBS: judgment after 2 years experience.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.
Topics: Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
[A case of pure akinesia with pheochromocytoma].
Topics: Adrenal Gland Neoplasms; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Pheochromocytoma | 1987 |
A novel nigrostriatal dopaminergic disorder in sheep affected by Tribulus terrestris staggers.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Efferent Pathways; Female; Levodopa; Movement Disorders; Phenylacetates; Plant Poisoning; Sheep; Sheep Diseases; Substantia Nigra | 1987 |
Evaluation of chronic levodopa therapy in Parkinson's disease.
Topics: Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1986 |
Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Domperidone; Ergolines; Female; Humans; Infusions, Intravenous; Levodopa; Lisuride; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1986 |
Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Bromocriptine; Butyrophenones; Female; Kinetics; Levodopa; Macaca fascicularis; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Spiperone; Time Factors | 1986 |
Simple and complex movements off and on treatment in patients with Parkinson's disease.
Topics: Adult; Aged; Electromyography; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Contraction; Parkinson Disease; Reaction Time | 1987 |
Carbidopa-levodopa therapy for movement disorders.
Topics: Basal Ganglia Diseases; Carbidopa; Craniocerebral Trauma; Drug Therapy, Combination; Humans; Levodopa; Movement Disorders | 1987 |
Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat.
Topics: Animals; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Female; Haloperidol; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Muscle Rigidity; Rats; Rats, Inbred Strains; Receptors, Adrenergic; Reserpine; Swimming; Sympatholytics; Time Factors; Tremor | 1987 |
Optimum symptomatic control of Parkinson's disease with dopaminergic therapy.
Topics: Aged; Bromocriptine; Drug Combinations; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1987 |
Mesulergine (CU 32-085) in the treatment of Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Drug Administration Schedule; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1986 |
An analysis of long-term L-dopa therapy in 122 cases of Parkinson's disease over 14 years--when should L-dopa therapy be initiated?
Topics: Adult; Aged; Female; Gait; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Parkinson Disease; Prognosis; Receptors, Dopamine; Time Factors; Tremor | 1986 |
Transdihydrolisuride in parkinsonism.
Topics: Aged; Blood Pressure; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Movement Disorders; Nausea; Parkinson Disease; Psychoses, Substance-Induced | 1987 |
Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Benserazide; Benzazepines; Callitrichinae; Levodopa; Male; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Tremor | 1985 |
[Useful data on parkinsonian syndromes].
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease, Secondary | 1985 |
The treatment of Parkinson's disease.
Topics: Aged; Bromocriptine; Carboxy-Lyases; Humans; Levodopa; Movement Disorders; Nausea; Parkinson Disease; Psychoses, Substance-Induced | 1985 |
Controversies in the treatment of Parkinson's disease.
Topics: Bromocriptine; Humans; Levodopa; Movement Disorders; Parkinson Disease; Time Factors | 1985 |
Auditory and somatosensory evoked potentials (AEPs and SEPs) and ballistic movements in Parkinson disease.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Electromyography; Evoked Potentials, Auditory; Evoked Potentials, Somatosensory; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1985 |
[Long-term evaluation of tiapride in patients with various forms of dyskinesia].
Topics: Benzamides; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Meige Syndrome; Movement Disorders; Safety; Tiapamil Hydrochloride | 1985 |
Stereotactic thalamotomy and L-dopa induced involuntary movement in Parkinsonism.
Topics: Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease, Secondary; Thalamus | 1973 |
The "on-off" effect.
Topics: Dopa Decarboxylase; Humans; Levodopa; Movement Disorders; Parkinson Disease; Tyrosine 3-Monooxygenase | 1974 |
Dopaminergic and cholinergic mechanisms in relation to postural tremor in the monkey and circling movements in the cat.
Topics: Acetylcholine; Amphetamine; Animals; Cats; Corpus Striatum; Disease Models, Animal; Dopamine; Frontal Lobe; Haloperidol; Haplorhini; Levodopa; Mesencephalon; Methyltyrosines; Mice; Movement Disorders; Parkinson Disease; Posture; Rats; Reserpine; Substantia Nigra; Tegmentum Mesencephali; Thalamic Nuclei; Tremor | 1974 |
Possible role of cerebellar circuits in parkinsonian symptoms.
Topics: Aged; Animals; Cats; Cerebellar Diseases; Cerebellum; Female; Haplorhini; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Neural Pathways; Parkinson Disease; Thalamic Nuclei; Tremor | 1974 |
[The problem of side effects after a treatment with L-dopa in the Parkinson's syndrome: clinical and animal studies (author's transl)].
Topics: Adult; Aged; Brain; Cardiovascular Diseases; Dopamine; Drug Eruptions; Female; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Pain; Paresthesia; Parkinson Disease, Secondary; Psychoses, Substance-Induced | 1974 |
Drug treatment of diseases characterized by abnormal movements.
Topics: Chorea; Diazepam; Ethanol; Haloperidol; Humans; Huntington Disease; Levodopa; Movement Disorders; Myoclonus; Phenothiazines; Propranolol; Reserpine; Tetrabenazine; Tic Disorders; Torticollis; Tourette Syndrome; Tremor | 1973 |
[Problems in the administration of L-DOPA (author's transl)].
Topics: Cardiovascular Diseases; Drug Eruptions; Gastrointestinal Diseases; Humans; Levodopa; Mental Disorders; Movement Disorders; Parkinson Disease; Urologic Diseases; Vision Disorders | 1974 |
Clinical features, etiology and treatment of facial dyskinesias in the elderly.
Topics: Age Factors; Aged; Brain; Brain Damage, Chronic; Brain Stem; Chorea; Dementia; Dopamine; Face; Female; Haloperidol; Humans; Intracranial Arteriosclerosis; Levodopa; Lip; Male; Movement Disorders; Parasympathomimetics; Parkinson Disease; Phenothiazines; Tongue | 1974 |
Unexpected findings with apomorphine and their possible consequences.
Topics: Administration, Oral; Antiparkinson Agents; Apomorphine; Chemical Phenomena; Chemistry; Dose-Response Relationship, Drug; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Humans; Injections, Subcutaneous; Levodopa; Movement Disorders; Parkinson Disease; Structure-Activity Relationship; Uremia | 1974 |
Dihydroxyphenylacetic acid in the treatment of Parkinsonism.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Levodopa; Movement Disorders; Parkinson Disease; Phenylacetates; Pyridoxine | 1974 |
The "on-off" response to chronic L-DOPA treatment of Parkinsonism.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Confusion; Dietary Proteins; Enzyme Inhibitors; Female; Gait; Humans; Levodopa; Male; Methyldopa; Movement Disorders; Muscle Cramp; Parkinson Disease; Time Factors | 1974 |
Variations in the "on-off" phenomenon.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Corpus Striatum; Enzyme Inhibitors; Humans; Levodopa; Movement Disorders; Parkinson Disease; Substantia Nigra | 1974 |
Plasma levodopa and the "on-off" effect.
Topics: Aged; Female; Humans; Levodopa; Movement Disorders; Parkinson Disease; Time Factors | 1974 |
Short- and long-term approaches to the "on-off" phenomenon.
Topics: Apomorphine; Carbidopa; Dietary Proteins; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Movement Disorders; Parkinson Disease; Time Factors | 1974 |
The "on-off" side effect of L-DOPA.
Topics: Age Factors; Amitriptyline; Aromatic Amino Acid Decarboxylase Inhibitors; Athetosis; Carbidopa; Catechol O-Methyltransferase Inhibitors; Chlordiazepoxide; Chorea; Desipramine; Diazepam; Dietary Proteins; Enzyme Inhibitors; Female; Humans; Imipramine; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Physical Exertion; Picolinic Acids; Prochlorperazine; Sex Factors; Stress, Psychological | 1974 |
Variations in the "on-off" effect.
Topics: Humans; Levodopa; Movement Disorders; Parkinson Disease; Time Factors | 1974 |
Levodopa, manganese, and degenerations of the brain.
Topics: Administration, Oral; Animals; Apomorphine; Blood Urea Nitrogen; Brain Diseases; Carbon Radioisotopes; Chemical Phenomena; Chemistry; Chronic Disease; Dietary Proteins; Dopamine; Drug Therapy, Combination; Growth Hormone; Humans; Injections; Levodopa; Manganese Poisoning; Movement Disorders; Neutron Activation Analysis; Parkinson Disease; Psychoses, Substance-Induced; Radioisotopes | 1974 |
L-dopa, parkinsonism, and involuntary movements.
Topics: Electromyography; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1974 |
Treatment of blepharospasm with levodopa.
Topics: Aged; Blepharospasm; Depression; Eyelid Diseases; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease | 1974 |
Plasma dopa concentrations and the "on-off" effect after chronic treatment of Parkinson's disease.
Topics: Dietary Proteins; Dihydroxyphenylalanine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Movement Disorders; Parkinson Disease | 1974 |
Parkinsonism as a falling sickness.
Topics: Age Factors; Aged; Amantadine; Female; Gait; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Neurologic Examination; Parasympatholytics; Parkinson Disease; Posture; Reflex; Remission, Spontaneous; Tremor | 1974 |
Parkinsonism and its treatment.
Topics: Antiparkinson Agents; Humans; Levodopa; Movement Disorders; Parkinson Disease; Stereotaxic Techniques | 1974 |